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NITD20, a member of indoline-spiro-tetrahydro-β-carboline class of compounds, was 
identified as a powerful inhibitor of Plasmodium falciparum proliferation. Synthetic studies in 
our laboratory showed that the synthesis of this compound exhibits high diastereoselectivity. This 
study investigated the reaction mechanism involved. Imine intermediates were synthesized, 
characterized and further cyclized at different temperatures to obtain indoline-spiro-tetrahydro-β-
carbolines of different diastereoselectivities. Control of the stereochemistry of the indoline-spiro-
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1.1. Malaria and its treatment 
 Malaria is an infectious disease caused by Plasmodium parasites, which are transmitted 
by Anopheles mosquitoes. The Plasmodium life cycle consists of several transitions and stages. A 
bite by the infected Anopheles mosquitoes will release sporozoites into the host to initiate a liver 
stage infection. After about a week, the infected hepatocytes will rupture and release merozoites 
which will move on to invade erythrocytes. The parasites will mature within 2-3 days and 
eventually turn to gametocytes that will be ingested by another Anopheles mosquito taking its 
next blood meal (1). Among the four Plasmodium species, namely falciparum, vivax, ovale and 
malariae, that cause malaria in humans, Plasmodium falciparum is the most virulent and is 
responsible for the majority of deaths from malaria. Plasmodium vivax and ovale are less deadly 
but the ability of these parasites to stay dormant in the liver makes them difficult to be resolved in 
the host. Similarly, Plasmodium malariae can exists as an asymptomatic blood stage infection for 
decades in the host (2). Clinical symptoms of malaria develop within 2-6 weeks of an infective 
bite and include fever and general weakness for uncomplicated cases and coma, pernicious 
anemia and pulmonary edema for complicated cases (3). 
In 2006, there were approximately 247 million malaria cases among 3.3 billion people at 
risk in the world. These infections translated to nearly a million deaths, mostly of children under 
the age of 5. In 2008, 109 countries were endemic for malaria and the disease is most prevalent in 
Africa (4). Under the Millennium Development Goals, a target was set to halt the rising incidence 
of malaria by 2015 (5). This rising awareness has led to an increase in the research efforts for this 
tropical disease over the recent years and progress in the areas of chemotherapies, vaccines, and 
diagnostics have raised hopes for delivery of interventions that will reduce the burden of this 
disease (2).  
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Historically, there is a long list of chemotherapeutic agents used for the treatment of 
malaria. In 1820, Pierre-Joseph Pelletier and Joseph Bienaimé Caventou extracted an alkaloid 
from the cinchona bark and named it quinine, giving rise to the world’s first effective treatment 
for malaria (6). Being extremely bitter and not well tolerated by patients when taken orally, 
quinine was soon replaced. When the WHO launched the Global Malaria Eradication Programme 
in 1955, chloroquine became the treatment of choice instead (7). However, chloroquine resistance 
was detected after several decades of use and drugs such as the sulfadoxine-pyrimethamine 
combination, proguanil, mefloquine and atovaquone (Figure 1) were subsequently introduced 
between the 1950s and 1990s to dampen the effects of chloroquine resistance. The emergence of 
resistance to these newer drugs proved to be even faster than chloroquine as drug resistance 
emerged after several years of use. Artemisinin (Figure 1), a natural product extracted from 
Artemisia annua, and its derivatives remain the only anti-malarial left with high potency and low 
resistance (2). Currently, artemisinin-based combination therapy (ACT), a combination of 
artemisinin derivatives with other active anti-malarials, is the most effective form of treatment 
against malaria (8). Studies have shown that using two or more drugs in combination has the 
potential to delay the development of resistance, (9) which explains the present adoption of 
combination therapies for the management of malaria. For example, Coartem, developed by 
Novartis and Chinese partners in 1994, is a combination of artemether and lumefantrine (Figure 
1). To date, more than 6 million patients have benefited from this treatment since its first 
registration in October 1998 (10). The combination of sulfadoxine and pyrimethamine is also 
commonly employed in the treatment of malaria in pregnant women. And in the event of severe 
multi-drug resistant malaria, quinine taken in combination with other antibiotics, such as 
doxycycline and clindamycin, is still an adequate treatment (8). However, the few current 
treatments of malaria are vulnerable to failure once compound-resistant parasites emerged. Thus, 
the lack of new anti-malarials in the clinical setting against different stages of the parasite is a 
serious threat for the treatment of malaria in the future. This has spurred research efforts on the 
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development of more ACTs and the discovery of novel anti-malarials, which are more potent, 
faster acting, minimally toxic and have chemical scaffolds different from the drugs in use. 
 
 
Figure 1 Structures of some common anti-malarials (* indicates a racemate; #mefloquine is a mixture 
of diastereomers) 
 
1.2. Screening and identification of potent growth inhibitor of Plasmodium falciparum  
At the Novartis Institute for Tropical Diseases (NITD), research efforts are directed 
towards finding a single dose cure for malaria caused by Plasmodium falciparum. After screening 
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a library of natural products with over ten thousand members for activity in a high-throughput 
cellular proliferation assay, NITD20 was identified as a powerful inhibitor of the parasite’s 
proliferation with a good pharmacological profile. This compound has a novel chemical scaffold 
(Figure 2) as compared to existing anti-malarials and its indoline-spiro-tetrahydro-β-carboline 
structure has two chiral centers. Re-synthesis of NITD20 via the Pictet-Spengler reaction yielded 
the product with high diastereoselectivity. After purification by column chromatography, NITD20 
was isolated and both the relative and absolute stereochemistry of the compound were determined 
by X-ray crystallography (Figure 3).  
 
 
Figure 2 Structure of NITD20 
 
 
Figure 3 X-ray crystal structure of NITD20 showing the crystallographic numbering of the atoms 
 
Intrigued by the mechanism behind the synthesis of NITD20, we sought a better 
understanding of the high diastereoselectivity observed with this spiro-tetrahydro-β-carboline 
compound.  
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1.3. The Pictet-Spengler reaction and control of its diastereoselectivity 
 Amé Pictet and Theodor Spengler first discovered the Pictet-Spengler reaction in 1911 
when they condensed phenethylamine with dimethoxyethane to produce tetrahydroisoquinoline 
(11). The reaction, which occurs in plants and humans, is now one of the most direct methods of 
forming the tetrahydro-β-carboline ring system (Figure 4), which is commonly found in indole 
and isoquinoline alkaloids. For example, the biosynthesis of indole-derived natural products 
utilizes the enzyme-mediated Pictet-Spengler reaction of tryptophan, tryptamine or dopamine 
with naturally occurring aldehydes as an essential step in the construction of the carbon skeleton 
(12). An example of such a Pictet-Spengler reaction is found in the biosynthesis of strychnine. 
 
 
Figure 4 Structure of a tetrahydro-ß-carboline 
 
 There are two possible pathways (Figure 5) for the reaction to proceed (13). A common 
imine intermediate is formed initially and attack at imine a can occur either directly via route 1 to 
form the pentahydro-β-carboline carbonium ion c or via route 2 followed by a rearrangement of 
the spiroindolenine b. With the help of an isotopic labeling experiment, Bailey et al. (14) 
demonstrated the formation of 3-aza-tetrahydro-β-carboline, from hydrazine and methanal in 
aqueous conditions, via the symmetrical spiro intermediate b (Figure 5). In this experiment, the 
authors hypothesized that if the attack at imine a occurred via route 1, the isotopic label would be 
localized at C1 of product d, whereas if the attack occurred via route 2, the label would be 
distributed between C1 and C4 of the product. The latter was achieved and the formation of the 
spiro intermediate was confirmed. Since imine formation is reversible in the presence of water, 
the formation of this spiro intermediate was determined to be fast and reversible and would not be 
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expected to affect the stereochemistry of the final tetrahydro-β-carboline product in a standard 
Pictet-Spengler reaction. On the other hand, the formation of the carbonium ion c was deduced to 
be the slow rate-determining step and energies of the cis and trans transition states should control 
the stereochemistry of the final product. In particular, for compounds with substituents at C1 and 
C3 of the tetrahydro-β-carboline ring structure (Figure 4), the Pictet-Spengler reaction can be 
used to establish the tricylic ring system with control of the stereochemistry at the chiral centers 
C1 and C3.  
 
 
Figure 5 Mechanism for the formation of the 3-aza-tetrahydro-β-carboline 
 
 Over the recent years, the stereospecific Pictet-Spengler reaction has seen many 
developments. Alberch et al. (15) reported the synthesis of cis-tetrahydro-β-carbolines via the 
Pictet-Spengler reaction of tryptophan allyl ester with aryl aldehydes under kinetically controlled 
conditions. Results showed that only allyl esters led to cis-stereospecificity in the reaction while 
propyl ester gave a mixture of diastereomers. Similarly, only aryl aldehydes condensed cis-
stereospecifically and alkyl aldehydes gave a mixture of diastereomers instead. A hypothesis that 
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favorable π-stacking interactions between the allyl and aryl groups allowed the cyclization to 
proceed through a di-axial intermediate leading to the formation of the cis diastereomer was put 
forward (Figure 6). Stabilization offered by π-stacking was postulated to overcome the steric 
strain associated with the di-axial conformation, thus forming the cis diastereomer. 
 
 
Figure 6 Proposed π-stacking between the allyl and aryl group in a di-axial intermediate 
 
 In another report, Ducrot et al. (16) were able to prepare diastereomerically pure 
tetrahydro-β-carbolines from reaction of α-aminoaldehydes with tryptamine. Experimental results 
showed that the use of bulky amino-protecting groups, led to the trans configuration while the use 
of smaller protecting groups led to the cis configuration. Furthermore, the cis diastereomer was 
formed exclusively under kinetic conditions. Under thermodynamic conditions, the 
diastereoselectivity was reversed and the amount of trans diastereomer formed was increased. 
The mechanism by which the cis and trans diastereomers may possibly interconvert under acid-
catalyzed thermodynamic conditions is shown in Figure 7 (17).  
Cox et al. (17) highlighted the influence of conformational effects on the 
diastereoselectivity of the Pictet-Spengler reaction. As illustrated in Figure 8, the spiroindolenine 
intermediate a resulting from attack 1 was less sterically hindered than c generated from attack 2. 
Subsequent rearrangement of the spiroindolenine intermediate along route 1 gave a more stable 
pentahydro-β-carboline carbonium ion b than d observed along route 2 because in b, the 
equatorial position occupied by the N-substituted phenyl group is more favorable than the axial 
position observed in d. These factors favored the generation of the trans diastereomer via route 1. 
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Figure 7 Proposed mechanism for the inter-conversion between the cis and trans configuration 
 
 
Figure 8 Different configuration of the imine intermediate yield different diastereomer 
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 Among the different mechanisms suggested by several groups, the one (13) proposed by 
Bailey et al. was seen to be the most relevant for this study. As shown in Figure 9, the common 
imine intermediate formed initially could be attacked via route 1 or 2. It has been shown that 
route 2 does occur but is not rate-determining and would not be a source of stereochemical 
control in the Pictet-Spengler reaction. Formation of the carbonium ion c was inferred to be rate 
determining instead. In this study, both routes would be taken into consideration for the 






































Figure 9 Possible mechanisms for the Pictet-Spengler reaction 
 
1.4. Pictet-Spengler reaction between methyl tryptamine and 5-chloroisatin 
The above-mentioned examples analyzed the tetrahydro-β-carboline structure for factors 
affecting the diastereoselectivity of the Pictet-Spengler reaction. However, limited information is 
available on the factors influencing the diastereoselectivity of the indoline-spiro-tetrahydro-β-
carboline system found in our compound of interest, NITD20. Pogosyan et al. reported the 
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synthesis of similar indoline-spiro-tetrahydro-β-carboline derivatives but provided no information 
on the mechanism and diastereomeric ratio (18). Kuo et al. highlighted the usage of microwave 
irradiation to accelerate the Pictet-Spengler reaction between tryptophan and ketones to give 1,1-
disubstituted tetrahydro-β-carbolines, but did not discuss the stereochemistry of the compounds 
or mechanism of the reaction (19). An attempt was made to elucidate the mechanism of the 
Pictet-Spengler reaction responsible for the high diastereoselectivity observed during the 
synthesis of NITD20. Furthermore, emphasis was placed on determining the influence of the 
configuration of the imine intermediate on the diastereoselectivity of the Pictet-Spengler reaction. 
The synthesis of NITD20 commenced from the reaction between S methyl tryptamine 
and 5-chloroisatin as shown in Figure 10. The reaction was refluxed at 110ºC with para-
toluenesulfonic acid as catalyst and ethanol as solvent. This set of conditions yielded NITD 20 
(trans diastereomer) as the major product and the cis diastereomer as the minor product and the 




























NITD 20 (trans) cis  
Figure 10 Synthesis of NITD20 
 
 For the mechanistic studies presented in this thesis, the racemic methyl tryptamine, which 
was synthetically more accessible, was used instead of the chiral methyl tryptamine. The chirality 
of methyl tryptamine will have no influence on the results as the diastereoselectivity was 
investigated and not the enantioselectivity. Using racemic methyl tryptamine, four structures 
could possibly be formed as illustrated in Figure 11. They are the two pairs of diastereomers 
(trans/cis) and the two pairs of enantiomers (cis/cis and trans/trans). The relative stereochemistry 
of all the products was assigned based on NMR and available X-ray crystallographic information. 
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The cis configuration is defined as having the two stereocenters on the ring in the same relative 
configuration while the trans configuration is defined as having the two stereocenters on the ring 
in the opposite relative configuration. 
 
 
Figure 11 Possible structures for trans and cis products 
 
The stability of the imine intermediates, the possibility of isomerization of the imines and 
the role of the imine configuration in governing the final stereochemistry of the indoline-spiro-
tetrahydro-β-carboline structure shown in Figure 10 remained uncertain. In order to obtain a 
better understanding of the importance of these factors, the isolation, study and full 
characterization of the imine intermediates were necessary. 
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2. Results & Discussion 
 Abadi et al. reported the synthesis of 2-indolone imine derivatives by condensation of 
isatin or haloisatin with amino acids or histamine (20). For example, histamine was condensed 
with 5-chloroisatin in refluxing ethanol at 1M concentration. Given the similarity between the 
imine derivatives synthesized by the authors and the imine intermediates in this study, the 
synthetic method was adopted. However, attempts to reproduce the reported results provided the 
cyclized product 7 instead of the imine derivative (Figure 12). In these attempts, the imine 
derivative a could not be obtained.  
 
 
Figure 12 Different results obtained from the condensation of histamine and 5-chloroisatin 
 
2.1. Investigation of imines formed between methyl tryptamine and 5-chloroisatin 
2.1.1. Synthesis and characterization of imines 1 and 2 
After some modifications to the procedure described by Abadi et al., the synthesis of the 
imine intermediates was successful. Imines 1 and 2 were obtained as mixtures of Z/E isomers 
from methyl tryptamine and 5-chloroisatin (Figure 13). The ratio of each mixture was determined, 
without purification, by comparing the integrated intensities of the methyl protons k in 1H NMR 
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and expressed as Z:E. An example of the difference in integration of methyl protons k of both 
isomers is illustrated in Figure 14. 
 
 
Figure 13 Synthesis of imine intermediate 
 
 
Figure 14 Integration of methyl protons k of both isomers 
 
 When methyl tryptamine was reacted with 5-chloroisatin in refluxing ethanol (80ºC) at 
0.95M concentration, a 1:8 isomer mixture was first isolated serendipitously as the solvent 
evaporated in the midst of the reflux and a yellow precipitate remained. When the same 
experiment was repeated in a sealed tube to prevent evaporation of the solvent, a pale yellow 
precipitate was obtained instead. Analysis of this solid revealed a 20:1 isomer mixture, in contrast 
to the 1:8 mixture obtained under the previous conditions. This 20:1 isomer mixture was 
reproducible under the conditions of 80ºC ethanol at 0.95M concentration, fully characterized and 
named imine 1 (58% yield).  
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 In an attempt to obtain the 1:8 isomer mixture again, the reaction mixture, at 0.95M 
concentration in 80ºC ethanol, was left to evaporate on purpose and a bright yellow solid was 
obtained as a 1:23 isomer mixture. It was hypothesized that due to the evaporation of ethanol, the 
1:23 isomer mixture was precipitated when the reaction mixture was more concentrated than 
0.95M. To test this hypothesis, two experiments were performed, where methyl tryptamine and 5-
chloroisatin were reacted in a sealed tube under 80ºC ethanol at 1.45M or 2.87M concentration, 
and the ratio of the isomer mixture obtained was 2:1 and 1:23 respectively. This phenomenon of 
different reaction concentrations providing distinct isomer mixtures has few or no precedents in 
the literature and is difficult to explain. It probably involves a complex reaction in which 
solubility and equilibration of imines each play a role in determining the final ratio of the isomer 
mixture and more research has to be done to explain these observations. Nonetheless, the set of 
reaction conditions, which yielded the 1:23 isomer mixture as a bright yellow precipitate, was 
reproducible and allowed the characterization of the isomer mixture. The 1:23 isomer mixture 
was named imine 2 (58% yield). 
Although characterization of both imines 1 and 2 by 1H NMR revealed a distinct set of 
chemical shifts for each isomer, the differentiation of isomers was not clear during the initial 
phase of this study. For example, the chemical shifts of the two isomers of proton j have a 
difference of about 1 ppm (Figure 15). Proton j of the Z isomer was predicted to appear more 
upfield in the 1H NMR spectra as it was thought to lie in a less electron-shielded position as 
compared to that of the E isomer. 
Eventually, the two isomers were distinguished from each other by NOESY-1D 
spectroscopy. Irradiation of proton j (refer to Figure 16 for nomenclature) was deduced to show a 
correlation with proton f in the E isomer while in the Z isomer, no correlation between protons j 




Figure 15 Chemical shifts of both isomers of proton j  
 
 
Figure 16 Structures of isomers E and Z 
 
 Figure 17a shows the 1H NMR spectrum of imine 2. Proton j exists as a multiplet with a 
chemical shift of 4.57-4.69 ppm and proton f exists as a doublet at 7.53 ppm. In contrast, proton j 
exists as a multiplet with a chemical shift of 5.56-5.66 ppm and proton f exists as a doublet at 
7.40 ppm (Figure 17b) for imine 1. When proton j of imine 2 was irradiated, an NOE correlation 
was observed with protons f, e and a (Figure 17c). Further irradiation of proton f also showed a 
correlation with proton j. This strong NOE correlation between protons f and j is a direct proof 
that imine 2 is the E isomer. On the other hand, imine 1 was confirmed to be the Z isomer as NOE 










Figure 17 NMR spectra of imines 1 (b) and 2 (a & c) in DMSO-d6 
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Besides differences in NOE correlation, imines 1 and 2 differ in other physical properties 
too. Imine 1 is a light yellow solid with a melting point range of 181.3-182.0ºC while imine 2 is a 
bright yellow solid with a melting point range of 168.0-169.2ºC. In addition, infrared (IR) 
spectroscopic analysis of the imines showed two distinct wavelengths for the imine bond. A 
summary of the differences between the E and Z isomers, which would allow their differentiation, 
is listed in Table 1. 
 
 Z-isomer (Imine 1) E-isomer (Imine 2) 
Physical appearance Light yellow solid Bright yellow solid 
Concentration of reaction mixture 
at which it precipitated out  
0.95 M 2.87 M 
Total time of reaction (time at 
which the precipitate was first 
observed during the reaction) 
1 hour 30 minutes (40 
minutes) 
1 hour (5 minutes) 
NOE Correlation (Figure 15) Correlation between 
protons e, a and j only 
Correlation between 
protons f, e, a and j 
Isomer ratio (Z:E) 20:1 1:23 
Melting Point 181.3-182.0ºC 168.0-169.2ºC 
Imine Bond (C=N) IR  1707 cm-1 1728 cm-1 
Table 1 Unique characteristics of E and Z isomers 
 
2.1.2. Stability of imines and observation of a thermodynamic mixture 
 Imines 1 and 2 are stable in solid form but decompose when subjected to standard HPLC 
conditions described under the experimental sections. When both imines were dissolved in 
dimethylsulfoxide (DMSO) and left to stand in solution at ambient temperature for 24 hours, a 
3:1 thermodynamic mixture was observed (Figure 18). No further isomerization was detected 
thereafter. It is proposed that imines 1 and 2 are both kinetic products obtained through 
precipitation from the reaction mixture. When more time was given for inter-conversion of the 




Figure 18 Equilibration of Z and E isomers to a common thermodynamic point 
 
 From the above finding, it was inferred that the Z isomer is more stable than the E isomer. 
Conformational effects could possibly explain the observed stabilities with the isomers. The E 
isomer adopts a more sterically hindered configuration (Figure 19) than the Z isomer and its 
formation is therefore less energetically favored as seen from the ratio of the thermodynamic 
mixture. It was further hypothesized that if a bulky group was substituted at the 4-position, a 
larger amount of steric hindrance observed in the E isomer would cause the formation of the Z 
isomer to be even more favorable.   
 
 
Figure 19 Steric hindrance observed in the E configuration 
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2.2. Investigation of imine formed between methyl tryptamine and 4-chloroisatin 
2.2.1. Synthesis and stability of imine 3 
 Imine 3 (Figure 20) was formed exclusively as its Z isomer in the reaction between 
methyl tryptamine and 4-chloroisatin under the conditions of 80ºC ethanol at 0.95M 
concentration. This result was in agreement with our previous prediction that a group bulkier than 
hydrogen at the 4-position of the isatin ring would have steric interactions with the indole ring 
and reduce the chance of the E configuration from being adopted (Figure 21). In the case of 4-
chloro, the formation of the E isomer was prevented. 
 
 
















Figure 21 Steric effects contributed by a bulky R group at the 4-position would reduce the chance of 
the formation of the E isomer  
 
 Unlike imines 1 and 2, imine 3 does not equilibrate when left to stand in DMSO solution 
for 24 hours. The Z isomer remained in solution without converting to the E isomer. This 
observation is another indication of the steric effects discussed above.  
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2.3. Investigation of imines formed between methyl tryptamine and 4-substituted isatins 
2.3.1. Synthesis of imines 4-6 
 After steric hindrance at the 4-position of the isatin ring had been shown to affect the 
stereochemistry of imine 3, investigation of electronic effects at the same position on the 
stereochemistry of the imine intermediates were carried out. Imines 4 and 5 (Figure 22) with 
substituents of different electronegativities, namely fluoride and methoxy, were synthesized. 
Imine 6 (Figure 22), formed from methyl tryptamine and isatin, served as a reference point. 
 
 
Figure 22 Structures of imines 4-6 
 
During the initial synthesis of imine 4 at 80ºC ethanol with a reaction concentration of 
0.95M, the cyclized product, as illustrated in Figure 23, was obtained instead. The ease of 
cyclization of imine 4 could be due to the electron withdrawing effect of fluorine, which might 
cause the imine bond to be more electrophilic. As the electrophilicity of the imine bond is the 
driving force for cyclization (17), this in turn might have led to a greater probability of attack at 
the imine bond (Figure 24).  
 
 





Figure 24 Electron-withdrawing effect of fluorine makes the partial positive center more positive 
 
To prevent the cyclization of the imine 4 from taking place, the temperature of the 
reaction was reduced to 50ºC and the reaction concentration was increased to 2.87M. With this 
set of reaction conditions, imine 4 was obtained as an orange gum with an isomer (Z:E) ratio 
mixture of 1:3.  
Both imines 5 and 6 were prepared by condensation of methyl tryptamine with 4-
methoxyisatin and isatin respectively under the conditions of 80ºC ethanol at 0.95M 
concentration. Imine 5 was obtained as a red brown gum with an isomer ratio of 4:1 and imine 6 
was isolated as a brown gum with an isomer ratio of 1:3. No sign of cyclization was observed 
during the synthesis of these imines.   
2.3.2. Initial ratios and stability of imines 4-6 
Imines 4-6 were dissolved in DMSO and 1H NMR was used to determine the initial ratios 
of these isomer mixtures. To observe the stability of these imines, the mixtures were left in 
solution at room temperature and the isomer ratios were re-determined after 24 hours (Table 2).  
Imine Isomer ratio 
(Z:E) 
Isomer ratio when left to stand for 24 hours in DMSO 
(Z:E) 
4 1:3 2:1 
5 4:1 9:1 
6 1:3 2:1 
Table 2 Comparison of isomer ratios of imines 4-6 
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 The results demonstrated that electronic effects at the 4-position do not influence the 
configuration of the imine. Instead, steric effects play a more important role. When a bulky group, 
such as methoxy, was introduced, the initial ratio of imine 5 was in favor of Z. Smaller 
substituents, such as fluoride and hydrogen, provided initial ratios in favor of E as seen in imine 4 
and 6. These ratios reflected the isomer mixture at the point of termination of the reactions and 
showed the favorable formation of the Z configuration in the presence of steric bulk at the 4-
position. However, once the imines were allowed to equilibrate at room temperature, all the ratios 
shifted to favor the Z isomer.  
When chloride was introduced at the 4-position as mentioned previously in section 2.2.1, 
the Z isomer was formed exclusively in imine 3. Both chloride and methoxy give similar steric 
effects but in terms of electronic effects, chloride is electron-withdrawing while methoxy is 
electron-donating. Despite the differences in electronic effects, both substituents produce imines 
that contain the Z isomer predominantly and this further supports our previous argument that a 
bulky group at the 4-position would lead to the formation of the Z configuration, which is 
energetically favored as it has less steric interactions than the E configuration. 
2.4. Cyclization of the imine intermediates 
2.4.1. Conditions of the cyclizations 
 The next stage of this study involved the acid-catalyzed cyclizations (Figure 25) of imine 
intermediates 1-3 at -78ºC, room temperature and 110ºC for 1 hour, 25 minutes and 10 minutes 
respectively. 10 equivalents of hydrochloric acid were used and ethyl acetate was used as the 
solvent. Ethyl acetate was chosen because it could dissolve the imine intermediate and previous 
work in our laboratory had shown that ethyl acetate gave similar diastereoselectivity as ethanol, 
which was the solvent used in the original synthesis of NITD20. All reactions were carried out in 






























Figure 25 Acid-catalyzed cyclization of imine 1 (* all possible structures for trans and cis products 
were shown in Figure 11) 
 
 The influence of the reaction temperature was studied and kinetic and thermodynamic 
products were obtained. By conducting the reaction in both anhydrous and non-anhydrous 
conditions, the influence of traces of water on the stereochemical outcome of the cyclization 
could also be observed.  
2.4.2. Diastereoselectivities of the cyclizations of imines 1 and 2 
 Imine 1 was cyclized as illustrated in Figure 25 and the results are summarized in Table 
3. Cyclization of imine 1 always gave the trans product 8 (Figure 25) as the major product with 
high diastereoselectivity regardless of the temperature or if traces of water were excluded or not. 
Under non-anhydrous conditions, the diastereomeric ratio was highest at -78ºC and decreased as 
the temperature of the reaction increased. When anhydrous conditions were employed instead, the 
diastereomeric ratios obtained at -78ºC and room temperature were similar to those obtained 
under the non-anhydrous conditions, showing that anhydrous conditions had no influence on the 
stereochemical outcome of the reaction at these temperatures. However, at 110ºC, the 
diastereomer ratio obtained under anhydrous conditions was about twice as high as that obtained 
under non-anhydrous conditions.  
  Diastereomer ratio (trans:cis) 
Temperature Non-anhydrous ethyl acetate Anhydrous ethyl acetate 
-78ºC 18:1 19:1 
Room temperature 12:1 11:1 
110ºC* 10:1 21:1 
Table 3 Diastereomer ratio of cyclized products of imine 1 (*reaction carried out in a sealed tube) 
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 Imine 2 was cyclized under the same conditions as imine 1 (Figure 26) and the results are 
shown in Table 4. At -78ºC, cyclization of imine 2 afforded the cis product 9 as the major product 
with high diastereoselectivity. As the temperature of the reaction was increased, the 
diastereomeric ratio was reversed and the trans product 8 was formed as the major product at 
110ºC. These trends were observed for both anhydrous and non-anhydrous conditions. Similar to 
imine 1, the diastereomer ratio obtained under anhydrous conditions was about twice as high as 





























Figure 26 Acid-catalyzed cyclization of imine 2 (* all possible structures for trans and cis products 
were shown in Figure 11) 
 
  Diastereomer ratio (trans:cis) 
Temperature Non-anhydrous ethyl acetate Anhydrous ethyl acetate 
-78ºC 1:20 1:22 
Room temperature 1:2 1:1 
110ºC* 7:1 15:1 
Table 4 Diastereomer ratio of cyclized products of imine 2 (*reaction carried out in a sealed tube) 
 
The results obtained from the cyclizations of imines 1 and 2 suggest that at -78ºC, the 
configuration of the imine intermediates dictates the stereochemistry of the cyclized products. 
The E isomer (imine 2) will cyclize to give the cis product 9 while the Z isomer (imine 1) will 
cyclize to give the trans product 8 at -78ºC. As the temperature was increased, such control was 
lost. At 110ºC, the imine configuration has no influence on the stereochemical outcome of the 
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reaction as both isomers cyclized to give the trans product. The increase in diastereomeric ratio at 
110ºC under anhydrous conditions was reproducible but no explanation could be offered at this 
point of time. An isotopic labeling experiment using deuterated water could be carried out to 
examine the role of water in the reaction and the results obtained might help to explain such an 
observation.  
To probe the cyclization conditions of the actual Pictet-Spengler reaction of NITD20, the 
3:1 (Z:E) thermodynamic mixture was cyclized. Equilibrating either of the imines preformed the 
3:1 mixture of imine 1 and 2. Cyclizations were carried out at the three different temperatures and 






























Figure 27 Acid-catalyzed cyclization of thermodynamic mixture (* all possible structures for trans 
and cis products were shown in Figure 11) 
 
  Diastereomer ratio (trans:cis) 
Temperature Non-anhydrous ethyl acetate 
-78ºC 1:1 
Room temperature 3:1 
110ºC* 11:1 
Table 5 Diastereomer ratio of cyclized products of thermodynamic mixture (*reaction carried out in 
a sealed tube) 
 
 Similar to the cyclizations of imines 1 and 2 separately, the formation of the trans 
product 8 was observed for the cyclizations of the thermodynamic mixture at high temperatures. 
Regardless of the ratios (Z:E) of the imines (20:1 for imine 1; 1:23 for imine 2; 3:1 for the 
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thermodynamic mixture) cyclized under non-anhydrous conditions at 110ºC, similar 
diastereomeric ratios (trans:cis) of the cyclized products (10:1 for the product of imine 1; 7:1 for 
the product of imine 2; 11:1 for the product of thermodynamic mixture) were achieved. These 
findings suggest that under thermodynamic conditions, the configuration of imine is not the 
source of stereochemical control but other intermediates of the reaction are determining the 
stereochemical outcome. 
2.4.3. Heating of cyclized products of imines 1 and 2  
Previously, in section 1.3, the isomerization of the tetrahydro-β-carboline compounds 
was illustrated in Figure 7. This mechanism was suggested to occur under acidic conditions and 
high temperatures and provide thermodynamic mixtures of the tetrahydro-β-carboline compounds 
(17). In order to determine whether such a mechanism was providing the stereochemical control 
for the cyclized products in this study, trans product 8 and cis product 9 were heated separately at 
110ºC in a sealed tube for 23 hours. 10 equivalents of hydrochloric acid were utilized and ethyl 
acetate was used as the solvent.  
 
 trans product 8 cis product 9 
Diastereomer ratio of 






Diastereomer ratio of 







Table 6 Diastereomer ratios of trans and cis products before and after heating 
 
 The results in Table 6 showed that isomerization of the cyclized products did not 
contribute significantly to the diastereoselectivity of the cyclization of the imine intermediates. A 
decrease in diastereomeric ratio for the cis product 9 was observed but even with 23 hours of 
heating, it was not enough to reverse the ratio to give the trans product 8. On the other hand, 
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when imine 2 was cyclized at 110ºC as mentioned in section 2.4.2, the diastereomeric ratio was 
reversed and the trans product 8 was generated after an hour of heating. In the case of this study, 
the isomerization of the cyclized products is probably too slow to have an effect on the 
stereochemistry of the products. 
2.4.4. Diastereoselectivity of the cyclization of imine 3 
Cyclization of imine 3 was performed under the same conditions as imines 1 and 2 



























Figure 28 Acid-catalyzed cyclization of imine 3 (* all possible structures for trans and cis products 



































Figure 29 Possible structures of trans and cis products from the cyclization of imine 3 
 
  Diastereomer ratio (trans:cis) 
Temperature Non-anhydrous ethyl acetate Anhydrous ethyl acetate 
-78ºC 165:1 123:1 
Room temperature 37:1 46:1 
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110ºC* 12:1 18:1 
Table 7 Diastereomer ratio of cyclized products of imine 3 (*reaction carried out in a sealed tube) 
 
 Cyclization of imine 3 always gave the trans product 10 as the major product. The cis 
product was never obtained predominantly. At -78ºC, the trans product 10 was formed in major 
excess since the Z isomer was formed exclusively during the synthesis of imine 3. As the 
temperature increased, the diastereomeric ratio decreased but the trans product remained the 









3. General Discussion 
Analogous to the mechanism proposed by Bailey et al. (Figure 9), the general mechanism 
of the Pictet-Spengler reaction between methyl tryptamine and 5-chloroisatin is shown in Figure 
30. Methyl tryptamine and 5-chloroisatin react to form imine intermediate a, which has to form a 
6-membered ring carbonium ion c before the final product is generated. The imine intermediate a 
could also form the 5-membered ring spiroindolenine intermediate b instead. However, this step 
of the reaction had already been proven in the literature to be fast and reversible and would not be 
expected to affect the stereochemistry of the final indoline-spiro-tetrahydro-β-carboline product 
d. Therefore, the configuration of the imine intermediate a was hypothesized to be an important 
factor in the formation of carbonium ion c, which would further determine the stereochemistry of 










































3.1. Imine configuration as a source of stereochemical control under kinetic conditions 
The results of this study support the hypothesis that the source of stereochemical control 
for the Pictet-Spengler reaction under kinetic conditions could come from the configuration of the 
imine intermediates. At -78ºC, imine 1 (Z isomer) and imine 2 (E isomer) cyclized to give trans 
product 8 and cis product 9 respectively. These mechanisms are presented in Figures 31 and 32.  
As shown in Figure 31, a chair-like transition state is assumed to form during the 
cyclization of imine 1. In this transition state, both the methyl group of methyl tryptamine and the 
phenyl group of the isatin ring lie in preferable pseudoequatorial positions, avoiding 1,3-diaxial 
strain. This would lead to the prediction that the formation of the trans product 8 is preferred, 


























Figure 31 Proposed mechanisms for the cyclization of imine 1 at -78ºC to give the trans product 8 
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 Likewise for the cyclization of imine 2, a similar transition state (Figure 32) is formed 
with the methyl group in a pseudoequatorial position and the phenyl group in a pseudoaxial 
position. The 1,3-diaxial strain is thus avoided and this would lead to the prediction that the 






























Figure 32 Proposed mechanisms for the cyclization of imine 2 at -78ºC to give the cis product 9 
 
3.2. Source of stereochemical control under thermodynamic conditions 
As illustrated in Figure 33, the formation of spiro intermediate b from imine intermediate 
a and the formation of carbonium ion c from both b and a are in equilibrium under 
thermodynamic conditions. Hence, the configuration of a would not be expected to affect the 
stereochemistry of the product. Indeed, experimental results showed that the trans product is 
formed regardless of the imine configuration at 110ºC. Furthermore, cyclization of imine 3 at 
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110ºC generated the cis product (minor product) even though imine 3 exists only in the Z 
configuration, which has been shown to preferably cyclize to the trans product under kinetic 
conditions. On the other hand, the final step in which carbonium ion c loses a proton to generate 
product d is irreversible and the configuration of the carbonium ion is postulated to determine the 
stereochemistry of the products. The carbonium ion can adopt two possible configurations (c1 and 
c2), which will each cyclize to give two different products. The phenyl group of the isatin ring in 
c1 lies in a pseudoequatorial position and will lead to the trans product, while the phenyl group in 
c2 lies in a pseudoaxial position, leading to the cis product. The pseudoequatorial position is more 
energetically favored and thus at 110ºC, the equilibrium lies in favor of the formation of c1, 

















































Figure 33 Proposed mechanisms for the Pictet-Spengler reaction under thermodynamic conditions 
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4. Conclusion and Outlook 
This study investigated the importance of the configuration of the imine intermediates in 
the control of the stereochemistry of the products of the Pictet-Spengler reaction between methyl 
tryptamine and 5-chloroisatin.  
The observation of a 3:1 (Z:E) thermodynamic mixture suggests that the Z isomer is more 
stable than the E isomer. Experimental results have also shown that under kinetic conditions, the 
Z isomer cyclized to give the trans product preferably while the E isomer cyclized to give the cis 
product preferably. Mechanisms for these cyclizations have been proposed. This direct correlation 
was lost when the cyclizations took place under thermodynamic conditions and both the Z and E 
isomers gave rise to the formation of the trans product predominantly. A hypothesis for this 
phenomenon is given and such results could explain the high diastereoselectivity, in favor of the 
trans product, observed with the Pictet-Spengler reaction for the synthesis of NITD20. 
 The synthesis and full characterization of the imine intermediates were also successfully 
carried out. The isolation of these imine intermediates allowed the investigation of the influence 
of the imine geometry on the diastereoselectivity of the reaction. 
 In conclusion, the synthesis of indoline-spiro-tetrahydro-β-carboline product through an 
imine intermediate has been achieved and control of the diastereoselectivity of the products has 
been demonstrated. This led to a better understanding of the importance of the imine 






5. Experimental Sections 
5.1. General Methods 
Materials and reagents were of the highest commercially available grade and used without further 
purification. Methyl tryptamine and 4-chloroisatin were obtained from the chemical archive of 
NITD. 
Thin layer chromatography (TLC) was carried out on Merck silica gel 60 F254 (2.5 × 7.5 cm) 
using UV light (λ = 254nm) for visualization. TLC data are given as the Rf value with the 
corresponding eluent system specified in brackets. 
1H NMR and 13C NMR spectra were determined on a Varian 300 Mercury spectrometer. A 
relaxation delay of 2 sec and 32 repetitions were performed to obtain the 1H NMR spectra while a 
relaxation delay of 1 sec and 1000 repetitions were performed to obtain the 13C NMR spectra. 
Chemical shifts (δ) are expressed in ppm. Splitting patterns are described as singlet (s), broad 
singlet (br.s.), doublet (d), doublet of doublet (dd), doublet of doublet of doublet (ddd), triplet (t), 
triplet of doublet (td), quartet (q) or multiplet (m).  
Infrared (IR) spectroscopic analyses were performed with an FT/IR-4100typeA machine. 
Melting point determinations were made on the Buchi B-540 melting point apparatus.  
LC-MS analyses were performed with an Agilent LC1100 coupled with Applied Biosystems 
API2000, using the following conditions: monolithic-C18, 50 × 4.6 mm column; mobile system 
of acetonitrile/water with 0.1% of formic acid with a gradient of 5-95% acetonitrile; run time of 4 
mins; UV 254 and 214 nm; and flow rate of 3 mL/min. High resolution MS was done at the 
Department of Chemistry, National University of Singapore. 
HPLC ratio determinations were made on an Agilent LC1100 HPLC, using the following 
conditions: SymmetryShield RP-18 3.5µm, 150 × 4.6 mm column; mobile system of acetonitrile/ 
water with 0.1% of formic acid with a gradient of 5-95% acetonitrile; run time of 20 mins; UV 
254 and 214 nm; and flow rate of 0.8 mL/min. 
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Flash chromatography was performed using a Teledyne ISCO CombiFlash® system using 
RediSep® Rf disposable Flash columns. Column chromatography was done on manually packed 
column of Merck silica gel 60 (0.040-0.063 mm). 
5.2. General Procedures 
5.2.1. General procedure for cyclization of imines at different temperatures 
The imine (1.0 eq) was suspended in ethyl acetate to give a yellow suspension. 4M hydrochloric 
acid (10.0 eq) in 1,4-dioxane was added to the suspension at -78ºC, room temperature or 110ºC 
and the reaction mixture was stirred for 1 hour, 25 minutes or 10 minutes respectively. 1M 
sodium hydroxide (3 mL) was added to quench the reaction, which was further extracted with 
ethyl acetate (2 x 8 mL). Purification of the crude mixture by column chromatography yielded the 
cyclized product. 
5.3. Synthesis of the imine intermediates 
(Z)-3-[(2-1H-indole-4-yl)isopropylimino]-5-chloroindolin-2-one (1) 
 
Methyl tryptamine (100.0 mg, 0.57 mmol) and 5-chloroisatin (104.2 mg, 0.57 mmol) were 
dissolved in dry ethanol (0.6 mL). The resulting clear orange red solution was stirred and heated 
at 80ºC for 1 hour 30 minutes. A yellow precipitate was observed after 40 minutes of stirring. 
After completion of the reaction, the precipitate was collected via filtration, washed with ethanol 
and dried under vacuum. The title compound was isolated as a light yellow powder (113.0 mg, 
0.33 mmol, 58% yield).  
HRMS: m/z: [M+H]+ 338; [M+Na]+ 360; [M-H]- 336. 
1H NMR (300 MHz, DMSO-d6): δ = 1.19 (d, J = 6.15 Hz, 3H, CH3), 2.88-3.01 (m, 2H, CH2), 
5.56-5.66 (m, 1H, CH), 6.84 (dd, J = 8.21, 0.59 Hz, Ar-H-h), 6.93 (ddd, J = 7.99, 6.96, 1.17 Hz, 
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1H, Ar-H-b), 7.03 (td, J = 7.47, 1.17 Hz, 1H, Ar-H-c), 7.10 (d, J = 2.34 Hz, 1H, Ar-H-e), 7.30 (d, 
J = 7.91 Hz, 1H, Ar-H-d), 7.40 (d, J = 2.05 Hz, 1H, Ar-H-f), 7.41 - 7.46 (m, 1H, Ar-H-g), 7.63 (d, 
J = 7.62 Hz, 1H, Ar-H-a) 10.76 (s, 1H, NH) 10.98 (br.s., 1H, NH). 
13C NMR (75 MHz, DMSO-d6): d = 21.3, 33.8, 56.2, 110.5, 110.6, 112.9, 113.0, 118.9, 119.0, 
122.1, 122.2, 123.4, 127.5, 128.3, 131.8, 135.7, 140.3, 150.1, 160.2. 
NOESY-1D (300 MHz, DMSO-d6): No correlation observed between protons j, f, e and a. 
Melting point: 181.3-182.0ºC. 
Imine bond (C=N) IR: 1707 cm-1. 
(E)-3-[(2-1H-indole-4-yl)isopropylimino]-5-chloroindolin-2-one (2) 
 
Methyl tryptamine (100.0 mg, 0.57 mmol) and 5-chloroisatin (104.2 mg, 0.57 mmol) were 
dissolved in dry ethanol (0.2 mL). The resulting clear orange red solution was stirred and heated 
at 80ºC for 1 hour. A yellow precipitate was observed after 5 minutes of stirring. After 
completion of the reaction, the precipitate was collected via filtration, washed with ethanol and 
dried under vacuum. The title compound was isolated as a bright yellow powder (113.0 mg, 0.33 
mmol, 58% yield).  
HRMS: m/z: [M+H]+ 338; [M+Na]+ 360; [M-H]- 336. 
1H NMR (300 MHz, DMSO-d6): δ = 1.33 (d, J = 6.15 Hz, 3H, CH3), 2.97-3.14 (m, 2H, CH2), 
4.57-4.69 (m, 1H, CH), 6.85 (d, J = 8.50 Hz, 1H, Ar-H-h), 6.96 (ddd, J = 7.91, 6.74, 1.17 Hz, 1H, 
Ar-H-b), 7.03 (td, J = 7.55, 1.32 Hz, 1H, Ar-H-c), 7.10 (d, J = 2.34 Hz, 1H, Ar-H-e), 7.28 (ddd, J 
= 7.77, 1.03, 0.88 Hz, 1H, Ar-H-d), 7.37 (dd, J = 8.50, 2.05 Hz, 1H, Ar-H-g), 7.53 (d, J = 2.34 
Hz, 1H, f), 7.59 (d, J = 7.62 Hz, 1H, Ar-H-a), 10.77 (s, 1H, NH) 10.93 (br.s., 1H, NH). 
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13C NMR (75 MHz, DMSO-d6): d = 20.6, 33.6, 58.9, 110.5, 111.8 112.4. 112.9, 117.2, 118.3, 
119.2, 122.2, 126.0, 127.3,127.7, 131.9, 135.6, 142.3, 151.0, 158.2. 
NOESY-1D (300 MHz, DMSO-d6): Correlation observed between protons j, f, e and a.  
Melting point: 168.0-169.2ºC. 




Methyl tryptamine (100.0 mg, 0.57 mmol) and 4-chloroisatin (104.2 mg, 0.57 mmol) were 
dissolved in dry ethanol (0.6 mL). The resulting clear orange solution was stirred and heated at 
80ºC for 2 hours 30 minutes. After completion of the reaction, the precipitate was collected via 
filtration, washed with ethanol and dried under vacuum. The title compound was isolated as a 
yellow powder (107.3 mg, 0.32 mmol, 55% yield).  
HRMS: m/z: [M+H]+ 338; [M+Na]+ 360; [M-H]- 336. 
1H NMR (300 MHz, DMSO-d6): δ = 1.20 (d, J = 6.15 Hz, 3H, CH3), 2.89-3.04 (m, 2H, CH2), 
5.63-5.73 (m, 1H, CH), 6.78 (dd, J = 7.77, 0.73 Hz, 1H, Ar-H-h), 6.93 (ddd, J = 7.99, 6.96, 1.17 
Hz, 1H, Ar-H-b), 6.99-7.06 (m, 2H, Ar-H-c & d), 7.13 (d, J = 2.34 Hz, 1H, Ar-H-e), 7.27-7.38 
(m, 2H, Ar-H-g & f), 7.66 (d, J = 7.62 Hz, 1H, Ar-H-a), 10.76 (s, 1H, NH) 11.05 (br.s., 1H, NH). 
13C NMR (75 MHz, DMSO-d6): d = 22.4, 34.7, 56.5, 109.9, 111.9, 112.4, 118.1, 118.8, 119.5, 
121.4, 124.2, 124.5, 128.2, 129.6, 134.1, 136.8, 146.4, 151.7, 159.2. 
Melting point: 169.4-170.3ºC. 





Methyl tryptamine (100.0 mg, 0.57 mmol) and 4-fluoroisatin (94.7 mg, 0.57 mmol) were 
dissolved in dry ethanol (0.2 mL). The resulting clear orange solution was stirred and heated at 
50ºC for 2.5 hours. After completion of the reaction, the volatile solvents were removed under 
high vacuum. The title compound was isolated as an orange gum (91.9 mg, 0.29 mmol, 100% 
yield).  
1H NMR (300 MHz, DMSO-d6): δ = 1.31 (d, J = 6.15 Hz, 3H, CH3), 3.09 (d, J = 6.15 Hz, 2H, 
CH2), 4.55-4.67 (m, 1H, CH), 6.67 (d, J = 9.38 Hz, 1H, Ar-H), 6.93-6.99 (m, 1H, Ar-H), 7.04 (td, 
J = 7.47, 1.17 Hz, 1H, Ar-H), 7.14 (d, J = 2.05 Hz, 1H, Ar-H), 7.30-7.35 (m, 2H, Ar-H), 7.56-
7.61 (m, 2H, Ar-H), 10.79 (br.s., 2H, NH & NH). 
(Z)-3-[(2-1H-indole-4-yl)isopropylimino]-4-methoxyindolin-2-one (5) 
 
Methyl tryptamine (100.0 mg, 0.57 mmol) and 4-methoxyisatin (101.7 mg, 0.57 mmol) were 
dissolved in dry ethanol (0.6 mL). The resulting clear orange solution was stirred and heated at 
80ºC for 2.5 hours. After completion of the reaction, the volatile solvents were removed under 
high vacuum. The title compound was isolated a red brown gum (190.0 mg, 0.57 mmol, 99% 
yield).  
1H NMR (300 MHz, DMSO-d6): δ = 1.19 (d, J = 6.15 Hz, 3H, CH3), 2.92-3.04 (m, 2H, CH2), 
3.86 (s, 3H, OCH3), 4.55-4.67 (m, 1H, CH), 6.47 (d, J = 7.74 Hz, 1H, Ar-H), 6.67 (d, J = 8.58 Hz, 
1H, Ar-H), 6.95-6.99 (m, 1H, Ar-H), 7.02-7.07  (m, 1H, Ar-H), 7.30-7.34 (m, 2H, Ar-H), 7.76 (d, 




Methyl tryptamine (100.0 mg, 0.57 mmol) and isatin (84.5 mg, 0.57 mmol) were dissolved in dry 
ethanol (0.6 mL). The resulting clear orange solution was stirred and heated at 80ºC for 2 hours. 
After completion of the reaction, the volatile solvents were removed under high vacuum. The title 
compound was isolated as a brown gum (173.5 mg, 0.57 mmol, 100% yield).  
1H NMR (300 MHz, DMSO-d6): δ = 1.33 (d, J = 6.15 Hz, 3H, CH3), 3.12 (d, J = 6.45 Hz, 2H, 
CH2), 4.62-4.76 (m, 1H, CH), 6.88 (d, J = 7.91 Hz, 2H, Ar-H), 6.98 (t, J = 7.03 Hz, 1H, Ar-H), 
7.06 (t, J = 7.47 Hz, 1H, Ar-H), 7.16 (d, J = 1.46 Hz, 1H, Ar-H), 7.30-7.37 (m, 2H, Ar-H), 7.59 
(t, J = 7.47 Hz, 2H, Ar-H), 10.82 (br.s., 1H, NH). 
5.4. Synthesis of cyclized products 
5'-chloro-3,5,6,7-tetrahydrospiro[imidazo[4,5-c]pyridine-4,3'-indolin]-2'-one (7) 
 
Histamine (100.0 mg, 0.90 mmol) and 5-chloroisatin (163.4 mg, 0.90 mmol) were dissolved in 
dry ethanol (0.9 mL). The resulting clear orange solution was stirred and heated at 80ºC for 5 
hours. After completion of the reaction, the pale brown precipitate was collected via filtration, 
washed with ethanol and dried under vacuum. The title compound was isolated as a pale brown 
powder (167.8 mg, 0.61 mmol, 68% yield).  
HRMS: m/z: [M+H]+ 275; [M-H]- 273. 
1H NMR (300 MHz, DMSO-d6): δ = 2.52-2.64 (m, 1H, CH2), 2.66-2.78 (m, 1H, CH2), 2.92 (br.s., 
1H, NH), 2.98-3.09 (m, 1H, CH2), 3.46-3.59 (m, 1H, CH2), 6.83 (d, J = 8.21 Hz, 1H, Ar-H), 6.98 
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(d, J = 2.34 Hz, 1H, Ar-H), 7.22 (dd, J = 8.20, 2.34 Hz, 1H, Ar-H), 7.33 (s, 1H, Ar-H), 10.30 
(br.s., 1 H) 11.85 (br.s., 1 H) 
13C NMR (75 MHz, DMSO-d6): δ = 22.9, 39.4, 62.6, 111.4, 125.1, 126.0 (2C), 128.8, 134.3, 




(Z)-3-[(2-1H-indole-4-yl)isopropylimino]-5-chloroindolin-2-one 1 (20.0 mg, 0.06 mmol), 
suspended in ethyl acetate (0.48 mL), was cyclized according to the general procedure at -78ºC. 
The title compound was isolated as an off white solid (20.1 mg, 0.06 mmol, 100% yield).  
HPLC: Rt 7.60 mins (94.9%); 8.03 mins (5.1%). 
LC-MS: Rt 1.52 mins; m/z (ESI): [M+H]+ 338; [M-H]- 336; Rt 1.70 mins; m/z (ESI): [M+H]+ 
338; [M-H]- 336. 
1H NMR (300 MHz, DMSO-d6): δ = 1.18 (d, J = 6.15 Hz, 3H, CH3), 2.42 (dd, J = 14.94, 10.55 
Hz, 1H, CH2), 2.79 (dd, J = 14.94, 3.52 Hz, 1H, CH2), 3.06 (d, J = 5.86 Hz, 1H, NH), 3.86-4.00 
(m, 1H, CH), 6.92 (d, J = 8.50 Hz, 1H, Ar-H), 6.95-7.01 (m, 1H, Ar-H), 7.02-7.06 (m, 2H, Ar-H), 
7.17 (d, J = 7.91 Hz, 1H, Ar-H), 7.32 (dd, J = 8.94, 2.20 Hz, 1H, Ar-H), 7.44 (d, J = 8.21 Hz, 1H, 
Ar-H), 10.43 (s, 1H, NH), 10.47 (br.s., 1H, NH). 
13C NMR (75 MHz, DMSO-d6): δ = 22.4, 30.2, 45.0, 62.6, 111.7, 111.8, 111.9, 118.5, 119.1, 





(E)-3-[(2-1H-indole-4-yl)isopropylimino]-5-chloroindolin-2-one 2 (20.0 mg, 0.06 mmol), 
suspended in ethyl acetate (0.48 mL), was cyclized according to the general procedure at -78ºC. 
The title compound was isolated as an off white solid (19.0 mg, 0.06 mmol, 95% yield).  
HPLC: Rt 7.53 mins (4.3%); 8.03 mins (95.7%). 
LC-MS: Rt 1.63 mins; m/z (ESI): [M+H]+ 338; [M-H]- 336; Rt 1.72 mins; m/z (ESI): [M+H]+ 
338; [M-H]- 336. 
1H NMR (300 MHz, DMSO-d6): δ = 1.23 (d, J = 6.45 Hz, 3H, CH3), 2.32 (d, J = 7.91 Hz, 1H, 
NH), 2.42 (dd, J = 15.38, 10.40 Hz, 1H, CH2), 2.91 (dd, J = 15.24, 3.81 Hz, 1H, CH2), 3.42-3.54 
(m, 1H, CH), 6.94-7.00 (m, 1H, Ar-H), 6.97 (d, J = 8.20 Hz, 1H, Ar-H), 7.03 (td, J = 7.40, 1.32 
Hz, 1H, Ar-H), 7.14-7.20 (m, 2H, Ar-H), 7.30 (dd, J = 8.20, 2.05 Hz, 1H, Ar-H), 7.45 (d, J = 7.62 
Hz, 1H, Ar-H), 10.60 (s, 1H, NH), 10.80 (br.s., 1H, NH). 
13C NMR (75 MHz, DMSO-d6): δ = 22.7, 30.4, 46.5, 63.6, 111.5, 111.8, 112.3, 118.6, 119.1, 




(Z)-3-[(2-1H-indole-4-yl)isopropylimino]-4-chloroindolin-2-one 3 (20.0 mg, 0.06 mmol), 
suspended in ethyl acetate (0.48 mL), was cyclized according to the general procedure at -78ºC. 
The title compound was isolated as an off-white solid (18.7 mg, 0.06 mmol, 94% yield).  
HPLC: Rt 7.99 mins (0.8%); 8.72 mins (99.2%). 
LC-MS: Rt 1.71 mins; m/z (ESI): [M+H]+ 338; [M-H]- 336. 
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1H NMR (300 MHz, DMSO-d6): δ = 1.19 (d, J = 6.45 Hz, 3H, CH3), 2.36 (dd, J = 14.94, 10.55 
Hz, 1H, CH2), 2.67 (d, J = 5.57 Hz, 1H, NH), 2.84 (dd, J = 14.94, 3.52 Hz, 1H, CH2), 3.87-3.99 
(m, 1H, CH), 6.85-6.94 (m, 2H, Ar-H), 6.94-7.05 (m, 2H, Ar-H), 7.17 (d, J = 7.33 Hz, 1H, Ar-H), 
7.29 (t, J = 7.91 Hz, 1H, Ar-H), 7.44 (d, J = 6.74 Hz, 1H, Ar-H), 10.51 (s, 1H, NH), 10.59 (br.s., 
1H, NH). 
13C NMR (75 MHz, DMSO-d6): δ = 22.5, 30.4, 45.0, 63.0, 109.3, 111.8, 112.0, 118.4, 118.9, 
121.6, 123.1, 127.0, 128.9, 130.1, 131.2, 131.6, 137.1, 145.5, 178.3. 
5.5. Synthesis of isatins 
4-Fluoro-1H-indole-2,3-dione (11) 
 
Chloral hydrate (1.79 g, 10.8 mmol) and sodium sulphate (10.23 g, 72.0 mmol) were dissolved in 
water (30 mL) and warmed up to 50ºC. 3-Fluoroaniline (0.87 mL, 9.0 mmol) was added to the 
reaction mixture, followed by 1M hydrochloric acid (6.1 mL). Hydroxylamine hydrochloride 
(2.25 g, 32.4 mmol) dissolved in water (20 mL) was subsequently added and the resulting mixture 
was subjected to reflux at 55ºC for 19 hours to give a cream colored precipitate. It was collected 
via filtration, washed with water and dried under vacuum. The dried precipitate was added in 
small portions to concentrated sulfuric acid (5.5 mL), which was pre-heated to 55ºC. During the 
addition, the temperature of the mixture was maintained between 55-65ºC and raised to 80ºC for 
15 minutes after all the precipitate had been added. It was then left to cool on ice and the cooled 
mixture was poured onto crushed ice (27 mL) and left to stand for 1 hour. A yellow precipitate 
was obtained and collected via filtration. The yellow precipitate was further dissolved in 2.5M 
sodium hydroxide (7 mL), which was pre-heated to 60ºC, and the solution was acidified with 
acetic acid (10 mL) at 35ºC. This mixture was left to stand overnight to obtain a yellow 
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precipitate. Filtration of the mixture afforded the title compound as a yellow crystalline solid 
(373.3 mg, 2.26 mmol, 25% yield). 
LC-MS: Rt 1.16 mins; m/z (ESI): [M-H]- 164. 
1H NMR (300 MHz, DMSO-d6): δ = 6.72 (dd, J = 9.23, 2.20 Hz, 1H, Ar-H), 6.85 (td, J = 9.08, 
2.34 Hz, 1H, Ar-H), 7.59 (dd, J = 8.06, 5.71 Hz, 1H, Ar-H). 
13C NMR (75 MHz, DMSO-d6): δ = 100.2 (d, J = 27.09 Hz), 109.4 (d, J = 23.77 Hz), 114.7, 
127.7 (d, J = 11.61 Hz), 153.48 (d, J = 13.82 Hz), 159.7, 166.3, 169.7. 
COSY (300 MHz, DMSO-d6): Proton b shows correlation with both a and c while proton a and c 
show correlation with only b. 
N-(3-Methoxy-phenyl)-2,2-dimethyl-propionamide (12a) 
 
m-Anisidine (4.5 mL, 40.6 mmol) was suspended in aqueous sodium bicarbonate (20 mL) and 
pivaloyl chloride (5 mL, 40.6 mmol), dissolved in dichloromethane (20 mL) was added slowly to 
the suspension at 0ºC. The reaction was stirred at 0ºC for 1 hour 20 minutes and an off white 
precipitate was finally obtained. Dichloromethane (20 mL) was added to dissolve the precipitate 
and extract the product from the aqueous layer. The organic layer was collected, dried over 
sodium sulfate and evaporated to dryness. The title compound was obtained as an off white solid 
(6.98 g, 33.7 mmol, 83% yield). 
TLC: Rf = 0.7 (hexanes:ethyl acetate 1:1). 
LC-MS: Rt 2.00 mins; m/z (ESI): [M+H]+ 208. 
1H NMR (300 MHz, DMSO-d6): δ = 1.32 (s, 9H, (CH3)3), 3.81 (s, 3H, O-CH3), 6.64-6.70 (m, 1H, 
Ar-H), 6.91-6.97 (m, 1H, Ar-H), 7.21 (t, J = 8.20 Hz, 1H, Ar-H), 7.33 (br.s., 1H, NH), 7.40 (t, J = 
2.34 Hz, 1H, Ar-H). 
 44 
[2-(2,2-Dimethyl-propionylamino)-6-methoxy-phenyl]-oxo-acetic acid ethyl ester (12b) 
 
N-(3-Methoxy-phenyl)-2,2-dimethyl-propionamide 12a (6.95 g, 33.5 mmol) was dissolved in 
anhydrous tetrahydrofuran (70 mL). 1.6M butyl lithium in hexanes (50.3 mL, 80.4 mmol) was 
added dropwise to the reaction mixture which was left to stir at 0ºC for 3 hours 50 minutes. 
Diethyl oxalate (5.5 mL, 40.4 mmol) was added at -78ºC and the reaction mixture was stirred for 
another 2 hours. The reaction was quenched with 1M hydrochloric acid (36 mL) and extracted 
with diethyl ether (3 x 100 mL). The organic layers were collected, dried over sodium sulfate and 
evaporated to dryness. The crude mixture was purified by flash chromatography (hexanes:ethyl 
acetate 4:1). The title compound was obtained as a pale yellow solid (8.09 g, 26.3 mmol, 79% 
yield). 
TLC: Rf = 0.3 (hexanes: ethyl acetate 4:1). 
LC-MS: Rt 2.50 mins; m/z (ESI): [M+H]+ 308; [M-H]- 306. 
1H NMR (300 MHz, DMSO-d6): δ = 1.21 (s, 9H, (CH3)3), 1.28 (t, J = 7.03 Hz, 3H, CH3), 3.82 (s, 
3H, O-CH3), 4.30 (q, J = 7.03 Hz, 2H, CH2), 6.93 (dd, J = 8.50, 0.88 Hz, 1H, Ar-H), 7.62 (t, J = 
8.35 Hz, 1H, Ar-H), 7.82 (dd, J = 8.35, 0.73 Hz, 1H, Ar-H), 10.61 (br.s., 1H, NH). 
4-Methoxy-1H-indole-2,3-dione (12) 
 
[2-(2,2-Dimethyl-propionylamino)-6-methoxy-phenyl]-oxo-acetic acid ethyl ester 12b (2.15 g, 
7.01 mmol) was dissolved in dimethoxyethane (30 mL). Aqueous 12N hydrochloric acid (1.75 
mL, 21.0 mmol) was added and the reaction mixture was refluxed at 86ºC for 21 hours 20 
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minutes. The volatile solvents were removed under reduced pressure and a red precipitate was 
observed. Filtration of the suspension yielded the title compound was obtained as a red crystalline 
solid (0.88 g, 5.0 mmol, 71% yield). 
LC-MS: Rt 1.01 mins; m/z (ESI): [M+H]+ 178; [M-H]- 176. 
1H NMR (300 MHz, DMSO-d6): δ =  3.86 (s, 3H, O-CH3), 6.45 (d, J = 7.62 Hz, 1H, Ar-H), 6.69 
(d, J = 8.50 Hz, 1H, Ar-H), 7.54 (dd, J = 8.64, 7.77 Hz, 1H, Ar-H), 11.00 (br.s., 1H, NH). 
13C NMR (75 MHz, DMSO-d6): δ = 56.5, 105.0, 106.5, 107.5, 141.4, 152.0, 158.8, 160.2, 181.2. 
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From the Novartis compound archive, NITD10 was identified to have good anti-viral 
activity in cellular dengue assays. In order to utilize the chemical proteomics technology for 
the identification of the target of NITD10, an analog of NITD10 that could be immobilized to 
a solid matrix and yet retained its biological activity had to be designed and synthesized. A 
primary amino group was considered to be the ideal functional group suitable for covalent 
coupling to the solid matrix. The structure-activity-relationship (SAR) between NITD10 and 
its target was first explored so that a suitable site for coupling of the immobilizable compound 
to the solid support could be located. When a potential site to be immobilized was identified 
in an analog, another new analog with an acetylated primary amino group at that position 
would be synthesized and screened for activity. This analog would be submitted for chemical 
proteomics analysis if it showed good in-vitro anti-viral activity. Unfortunately the synthesis 
efforts were unable to identify a site where an acetylated primary amino group could be 
incorporated into the scaffold without affecting the activity of the compound. The synthetic 












List of Tables 
 
Table 1 Biological activities of compounds with modifications at site A (activities of 
potential immobilized compounds are highlighted in bold) ................................62 
Table 2 Biological activities of compounds with modifications at site B (activities of 
potential immobilized compounds are highlighted in bold) ................................62 
Table 3 Biological activities of compounds with modifications at site C (activities of 




List of Figures 
 
Figure 1 Immobilization of the analog to the solid support.........................................50 
Figure 2 A simple illustration of the chemical proteomics technology .......................50 
Figure 3 Struture of NITD10 .......................................................................................51 
Figure 4 Sequence of events for the design and synthesis of the immobilizable 
compound.............................................................................................................52 
Figure 5 Synthetic scheme for compounds 1-17, 33-34 & 36 .....................................53 
Figure 6 Synthetic scheme for compound 37 ..............................................................54 
Figure 7 Synthetic scheme for compounds 29-32........................................................55 
Figure 8 Synthetic scheme for compound 35 ..............................................................55 
Figure 9 Synthetic scheme for intermediates 18-21a...................................................56 
Figure 10 Synthetic scheme for compounds 18-21......................................................56 
Figure 11 Synthetic scheme for compound 26 ............................................................57 
Figure 12 Synthetic scheme for compounds 27-28......................................................57 
Figure 13 Synthetic scheme for compounds 22-25......................................................58 
Figure 14 A simple illustration of a possible π-π interaction between the electron-












1.1. Dengue and the need for a cure 
Dengue fever is currently endemic in more than one hundred countries in Africa, the 
Americas, the Eastern Mediterranean, South-East Asia and the Western Pacific. Among these 
tropical and sub-tropical regions, South-East Asia and the Western Pacific are most seriously 
affected (1). The World Health Organization (WHO) estimated that to date 2.5 billion people, 
two fifths of the world’s population, are at risk of dengue infection. Due to reduced mosquito 
control efforts, many epidemics have occurred over the past few decades (2). Annually, there 
are about 50 million reported cases of dengue worldwide (3).  
 The dengue virus belongs to a large family of viral pathogens called Flaviviradae and 
has four antigenically distinct serotypes. Infection with one of these serotypes provides 
immunity to only that serotype for life. The virus is transmitted to humans by the Aedes 
mosquitoes, mainly Aedes aegypti (4). After a viral incubation period of about eight to ten 
days, the mosquito will be able to transmit the virus for the rest of its life (3). 
 Symptoms of dengue fever include headache, rash, bone and muscular pains and 
leucopenia (3). Dengue hemorrhagic fever (DHF) is a more serious complication of dengue 
fever. It can occur during the first infection but is more commonly due to sequential 
infections by different serotypes of the dengue virus where antibody-dependent enhancement 
(5) of the infection could take place. DHF is classified by four major clinical symptoms, 
namely high fever, hemorrhagic tendency, thrombocytopenia and plasma leakage (6). There 
are approximately 500,000 cases of DHF per year and a large proportion of these cases affect 
children. Given the severity of its clinical manifestations, DHF has become a leading cause of 
hospitalization and death among children in some Asian countries (3). Studies, using the non-
monetary composite index called ‘disability-adjusted life years’ (DALYs) to measure the total 
impact of both morbidity and mortality of dengue fever and DHF, have highlighted that in the 
developing world, dengue fever and DHF have a total socioeconomic impact of the same 
order of magnitude as many of the major infectious diseases, such as malaria, tuberculosis 
 49 
and hepatitis (7). However, dengue has received less attention and funding from international 
funding agencies as compared to those major infectious diseases (7).   
 Currently, there is no approved vaccine or effective anti-viral drug to cure dengue. 
Patients infected with dengue are treated based upon their symptoms. Therefore, it is 
extremely urgent for more efforts and funding to be channeled into the development of a 
vaccine, which can target all four serotypes of the virus, or an anti-viral drug, which can 
inhibit the proliferation of the dengue virus. 
1.2. The use of chemical proteomics in dengue drug discovery campaigns 
Target finding is usually the first step in the drug discovery process of any disease 
area. Likewise for dengue, identification of a druggable target is important for subsequent 
lead optimization work. Potential targets for dengue include essential viral enzymes 
associated with the life cycle of dengue and host targets that interact with the virus during its 
replication in the host (8, 9). Many methods can be employed to find these targets. siRNA 
(small interfering ribonucleic acid) (10), gene knock out (10) and Cellzome’s chemical 
proteomics technology (11) are a few examples. 
The approach presented in this study is the Cellzome’s chemical proteomics 
technology (11). In this technology, the active compound is attached to a solid support. Since 
most of the compounds of interest usually do not contain functional groups suitable for 
covalent coupling to the solid matrix, analogs (also known as immobilizable compounds) 
containing primary amino group, which can be coupled to the solid support via an amide bond 
while maintaining the intrinsic biological activity of the compound, are synthesized. An 
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Figure 1 Immobilization of the analog to the solid support 
 
 By running cell lysates over these tethered compounds, specific protein target-
compound interactions could be captured (Figure 2). The bound proteins are eluted out with 
an affinity gradient and digested with trypsin. The genuine protein targets are then identified 
by mass spectrometric analysis. Once these protein targets are validated with assays, such as 
site-directed mutagenesis (12), they can be the starting points for drug discovery campaigns.  
  
 
Figure 2 A simple illustration of the chemical proteomics technology 
 
1.3. Identification of NITD10 as an inhibitor of dengue proliferation 
From the Novartis compound archive, NITD10 (Figure 3) was determined to have 
good anti-viral activity (IC50 of 0.5 µM) in cellular dengue assays. However, the target of 
NITD10 was not known and a structure-based drug discovery program was not possible 
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without having a validated and druggable target. With the design and synthesis of an 
immobilizable compound of NITD10, the chemical proteomics technology could be utilized 






Figure 3 Struture of NITD10 
 
To be suitable for coupling onto the solid matrix, the immobilizable compound has to 
contain a primary amino group and still retain an IC50 activity of less than 1.0µM in the 
cellular dengue assay. In order to aid the incorporation of the primary amino group onto an 
appropriate site on the scaffold of NITD10, the structure-activity relationship (SAR) of 
NITD10 with its target has to be established. 
 Herein, we report the synthesis of analogs of NITD10 in an attempt to find an 
immobilizable compound for target pull-down using the chemical proteomics technology. The 
SAR established will also be highlighted.  






Modifications were made at sites A, B and C (Figure 4) for the synthesis of analogs. 
The SAR of NITD10 was first explored with analogs that do not contain a primary amino 
group. When a potential site to be coupled was identified in an analog, a new analog a with a 
primary amino group at that position would be synthesized and tested for activity. The 
primary amino group would also be further acetylated to give analog b. This step would 
mimic the amide bond formation and determine whether analog a would lose its biological 









Addition of primary amino group












Acetylation of primary amino group
O
Testing in cellular dengue assays




analog a submitted for
chemical proteomics  
Figure 4 Sequence of events for the design and synthesis of the immobilizable compound 
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in the cellular dengue assays, analog a would be submitted for chemical proteomics analysis. 
2.1. Synthesis of analogs of NITD10 
Thirty-seven analogs were synthesized and tested in the cellular dengue assays. The 
design and biological activities of these analogs were the main focus of this study. Therefore, 
as long as the reactions yielded the desirable compounds, they were not further optimized to 
give better yields. 
2.1.1. Structural modifications at site A 
Synthesis of compounds 1-17, 33-34 & 36 were achieved by coupling commercially 
available substituted arylboronic acids with a common intermediate, 2-[(E)-3-(2-bomo-
phenyl)-acryloylamino]-benzoic acid methyl ester, using a palladium-catalyzed and 
microwave-assisted Suzuki reaction (Figure 5). The reaction was carried out under basic 
conditions and 1,4-dioxane was used as the solvent. These reactions proceeded with moderate 

















Microwave, 130oC, 30 minutes
1: R1 = 4-CH3
2: R1 = 4-C(CH3)3
3: R1 = 5-CF3
4: R1 = 4-OCH3
5: R1 = 4-N(CH3)2
6: R1 = 4,5-OCH3
7: R1 = 4-CF3
8: R1 = 4-F
9: R1 = 4-CH2OH
10: R1 = 2-CH3
11: R1 = 3-CH3
12: R1 = 3- NH2, 4-CH3
13: R1 = 3-NHCOCH3, 4-CH3
14: R1 = 4-(CH2)3CH3
15: R1 = 2-CH3, 6-CH3
16: R1 = 4-NO2
17: R1 = 3-NHCOOC(CH3)3
33: R1 = 4-C(CH3)2CH2NH2
34: R1 = 4-(CH2)2NO2
36: R1 = 4-(CH2)2NH2
1-17, 33-34 & 36
25 - 79% yield
 
Figure 5 Synthetic scheme for compounds 1-17, 33-34 & 36 
 
 Previous reports indicated that even though steric hindrance of aryl halides is not a 
major factor for the generation of substituted biaryls, low yields are obtained when ortho-di-
substituted arylboronic acids are used for the coupling (13). When compared to compound 11, 
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which was coupled from an arylboronic acid that has a methyl group substituted at the meta 
position and has a yield of 70%, a lower yield of 48% was indeed observed with the synthesis 
of compound 15 as the arylboronic acid it was coupled from has bulky groups at both ortho 
positions that might hinder the transmetalation step of the coupling cycle. 
 Electron-withdrawing or electron-donating substituents on the arylboronic acids used 
in this study did not exert a significant effect on the coupling reaction. No association of the 
yields with electronic effects was observed. For example, compound 16, with a nitro 
substituent, had a yield of 46% and compound 4, with a methoxy substituent, had a similar 
yield of 47%. Huang et al (14) reported similar findings indicating that electronic factors of 
the aromatic halides were significant while electronic effects of the arylboronic counterparts 
were negligible. 
 Coupling of 2-[(E)-3-(2-bomo-phenyl)-acryloylamino]-benzoic acid methyl ester 
with 4-pyrazoleboronic acid pinacol ester (Figure 6) using the same Suzuki conditions 
mentioned above also gave compound 37 in good yield (69%). This could indicate that 
various functional groups could be tolerated on the arylboronic acids used for coupling under 





















Figure 6 Synthetic scheme for compound 37 
 
 Compounds 29 and 30 (Figure 7) were originally Boc-protected when retrieved from 
the Novartis compound archive. Boc-deprotection with trifluoroacetic acid (TFA) yielded 
both compounds, as TFA salts, in excellent yields. Subsequent acetylation of both compounds 
with acetic anhydride and catalytic amounts of triethylamine provided compounds 31 and 32 
(Figure 7). These acetylation conditions were also employed for the synthesis of compound 
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35 from compound 33 (Figure 8). The use of catalytic amounts of base was not ideal and 
























29: R2 = CH2NH230: R2 = C4H9N2
31: R2 = C4H8N232: R1 = CH2NH
96 - 100% yield
42 - 49% yield
 

















Figure 8 Synthetic scheme for compound 35 
 
2.1.2. Structural modifications at site B 
Previous work in our laboratory has shown that the carboxylic acid at site B is 
essential for activity and could not be a coupling site. Thus, it was left intact in the analogs 
synthesized. 
Intermediates 18-21a were obtained by esterification of the corresponding benzoic 
acids with trimethylsilyl diazomethane (Figure 9). These intermediates were subsequently 
coupled with (E)-3-biphenyl-2-yl-acrylic acid chloride to give compounds 18, 20, 21 and 
intermediate 19b (Figure 10). Pyridine and dimethylaminopyridine (DMAP) were utilized as 
catalysts and dimethylformamide (DMF) was used as the solvent. As the methyl ester group 
of 19b did not hydrolyze during the microwave process, it was subsequently hydrolyzed with 
4M lithium hydroxide (LiOH) in a mixture of tetrahydrofuran and water. The yields of the 
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amide coupling reactions were generally low, and were due to decomposition of the reaction 
mixtures under the microwave conditions of 130ºC for about 5-6 hours. Such conditions were 












18a: R1 = 4-OCH319a: R1 = 4-CH320a: R1 = 6-CH321a: R1 = 5-CH3
53-94% yield
 






O 18, 20, 21a
Pyridine, DMF, DMAP
Microwave, 130oC



















18: R1 = 4-OCH319: R1 = 4-CH320: R1 = 6-CH321: R1 = 5-CH3
 
Figure 10 Synthetic scheme for compounds 18-21 
 
 Compound 26 was synthesized under the same conditions as compound 19 (Figure 
11) and a low yield was also observed in the amide coupling step due to decomposition of 
reaction mixtures under the harsh microwave conditions.  
As shown in Figure 12, amide coupling of (E)-3-biphenyl-2-yl-acrylic acid chloride 
with commercially available methyl-3-amino-4-nitrobenzoate gave compound 27 in moderate 
yield (50%). Subsequent reduction of the nitro group of compound 27 with tin (II) chloride 



















































Tin (II) chloride dihydrate











Figure 12 Synthetic scheme for compounds 27-28 
 
2.1.3. Structural modifications at site C 
The synthetic scheme for compounds 22-25 is illustrated in Figure 13. Intermediate 
22a was prepared from commercially available 2-bromo-4-nitrobenzaldehyde and methyl 
diethyl phosphonoacetate by a Horner-Wadsworth Emmons reaction. Butyllithium (BuLi) 
was used as a base and tetrahydrofuran (THF) was used as the solvent. Hydrolysis of the 
methyl ester in intermediate 22a, using 4M LiOH, provided intermediate 22b. The acid 
chloride of intermediate 22b was prepared using thionyl chloride. The amide coupling 
reaction between the acid chloride and methyl anthranilate used pyridine and DMAP as 
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catalysts and DMF as solvent and was stirred at room temperature for 20 hours. This milder 
condition, as compared to the microwave conditions, provided intermediate d with an 
improved yield of 60%. Suzuki coupling of intermediate d with phenylboronic acid or 4-tert-
butylphenylboronic acid yielded compounds 22 and 23 respectively. Subsequent reduction of 






















































22: R1 = H23: R1 = C(CH3)3
Tin (II) chloride dihydrate








24: R1 = H25: R1 = C(CH3)3




Figure 13 Synthetic scheme for compounds 22-25 
 
2.2. Biological testing of analogs  
Compounds 1-58 (synthesis of compounds 38-56 was performed by a contract 
research organization, GVK Biosciences and compounds 57-58 were synthesized in-house 
previously) were evaluated for their in-vitro anti-viral acitivity in the in-house cell-based 
flavivirus immunodetection (CFI) assay. This assay is based on quantitative immunodetection 
of viral envelope protein, E, as a readout for viral load in target cells. Both the IC50 and CC50 
(half maximal cytotoxic concentration) values were determined to distinguish anti-viral 
activity from cytotoxcitiy.  
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2.2.1. Evaluation of analogs with modifications at site A 
Site A is amendable to modifications and several analogs have desirable activities. 
However, these analogs did not have a primary amino group in their scaffold for 
immobilization onto the solid matrix. On the other hand, potential immobilizable compounds, 








Compound R1 IC50 (µM) CC50 (µM) 
1 
 0.4 47.5 
2 





 2.9 34.3 
4 O
 1.5 38.0 
5 N
 1.4 50.6 
6 O
O
 12.9 34.5 
7 F F
F
 0.7 18.3 
8 F
 1.3 26.6 
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Compound R1 IC50 (µM) CC50 (µM) 
9 HO
 15.5 33.8 
10 
 0.4 13.5 
11 
 0.4 18.3 
12 
H2N
 6.8 27.2 
13 H
N
O  45.6 68.1 
14 
 2.89 31.1 
15 
 1.01 42.3 
16 NO2
 1.4 17.1 
17 HNO
O
 5.4 19.6 
29 H2N












































    
    



































































































































    












Table 1 Biological activities of compounds with modifications at site A (activities of potential 
immobilized compounds are highlighted in bold) 
 
2.2.2. Evaluation of analogs with modifications at site B 
Site B does not tolerate changes and most of the analogs synthesized do not have the 
desired anti-viral activity in the CFI assay. Compound 57 is an exception and showed 














Compound R2 R3 IC50 (µM) CC50 (µM) 
18 4-OCH3 -- 13.6 42.0 
19 4-CH3 -- 50.5 78.6 
20 6-CH3 -- 36.2 68.6 
21 5-CH3 -- 10.0 48.0 
26 -- OCH3 27.6 >100 
27 -- NO2 24.3 51.4 
28 -- NH2 >100 >100 
42 5-NHCOCH3 -- 46.3 >100 
43 5-NH2 -- 74.8 74.2 
44 4-NH2 -- 33.5 72.1 
45 5-CH2NH2 -- 51.7 >100 
46 5-CH2NHCOCH3 -- >100 >100 
56 4-NHCOCH3 -- >100 >100 
57 4-Cl -- 2.5 32.3 
58 5-Cl -- 12.0 34.8 
Table 2 Biological activities of compounds with modifications at site B (activities of potential 
immobilized compounds are highlighted in bold) 
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Compound R4 R5 IC50 (µM) CC50 (µM) 
22 H 5-NO2 0.7 >100 
23 4-C(CH3)3 5-NO2 1.5 19.6 
24 H 5-NH2 10.8 >100 
25 4-C(CH3)3 5-NH2 0.8 57.6 
38 H 6-NH2 13.9 54.9 
39 H 4-NH2 22.1 60.8 
40 H 4-NHCOCH3 >100 >100 
41 H 6-NHCOCH3 93.6 72.0 
50 H 4-CH2NH2 >20 >20 
52 H 4-CH2NHCOCH3 >100 >100 
53 H 5-CH2NHCOCH3 >100 >100 
54 H 5-CH2NH2 >100 >100 
Table 3 Biological activities of compounds with modifications at site C (activities of potential 
immobilized compounds are highlighted in bold) 
 
As shown in Table 3, site C is also not as amendable to changes as site A. When 
primary amino groups were introduced, only compound 25 had an IC50 of less than 1.0µM. 
However, once the primary amino groups were acetylated, all inhibitory activity in the CFI 





3.1. Search for the immobilizable compound 
The design and synthetic efforts carried out in this study were unable to yield an 
immobilizable compound for the target pull down of NITD10 using the chemical proteomics 
technology. Several reasons could be attributed to it. 
 Being a small molecular weight compound, NITD10 (molecular weight of 343) 
could possibly be embedded in its target and majority of the scaffold has key interactions with 
the target. Thus, locating a site, which is synthetically accessible, for the immobilization of an 
analog, would be difficult. Furthermore, this study did not explore the middle region of the 
scaffold where the double bond and amide bond reside. This region could be a potential site 
and more research has to be performed to explore such a possibility.  
NITD10 could also be a non-specific cytotoxic agent and have interactions with 
multiple targets. A site that does not have major interactions with one target might form 
important bonds with another target. In this scenario, the chance of finding a site that does not 
have any key interactions with any of its targets would be low.  
3.2. Structure activity relationships of NITD10 with its target 
  This study explored some of the interactions of NITD10 with its target. The SAR will 
be presented in the subsequent paragraphs. 
3.2.1. Interactions at site A 
Compounds that contain alkyl groups, in the form of a single methyl group 
(compound 1, 10 and 11) or a t-butyl group (compound 2), have improved activities in the 
CFI assay as compared to NITD10. This suggests that there are important hydrophobic 
interactions between these alkyl groups and a non-polar surface area of the target. The 
interaction of these two non-polar surfaces reduces the amount of structured water at the 
interface and thus, provides a favorable entropy of association. The overall strength of the 
hydrophobic interaction is very dependent on the quality of the steric match between the two 
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surfaces (15) and this was demonstrated in compounds 2 and 14. Both compounds contain the 
same number of carbons in their alkyl side chains, but compound 2, being a compact 
molecule, is more active than compound 14, which has an extended n-butyl chain substituted.  
 The presence of phenyl rings could lead to possible π-π interactions between the 
phenyl ring and an electron-rich area on the target. It was postulated that by rendering the 
phenyl ring more electron-deficient with the presence of electron-withdrawing groups, such 
as CF3, NO2 and F, it could achieve a stronger π-π interaction with the electron dense region 
(Figure 14). On the other hand, when electron-donating groups, such as OCH3 and N(CH3)2, 
are substituted, the phenyl ring, being more electron rich, would form a weaker interaction 
with the electron-rich region and the activity of the compound is predicted to decrease. 
However, experimental results showed that electronic factors do not govern the activity of the 
compound. Compound 5, which contains a strong electron-donating N-dimethyl group, 
exhibited the same activity as compound 16, which contains a strong electron-withdrawing 
nitro group. Likewise for compounds 4 and 8, similar activities were observed for both even 
though compound 4 has an electron-donating methoxy group substituted and compound 8 





Figure 14 A simple illustration of a possible π-π interaction between the electron-deficient 
phenyl ring and an electron-rich area on the target 
  
The introduction of a primary amino group at site A did not favor the interaction of 
the compound with its target. As seen from compounds 12, 29 and 3, there were only 
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moderate activities observed in the CFI assays. Acetylation of these primary amines caused a 
further decrease in the in-vitro anti-viral activities. This was reflected in compounds 13, 32 
and 51 respectively.  
In summary, the optimal substituent at site A could simply be a single methyl group, 
which could introduce favorable hydrophobic interactions between the compound and its 
target.  
3.2.2. Interactions at site B 
As seen from the biological activities of analogs with modifications at site B, this part 
of the scaffold does not tolerate changes and activity was lost when substitutions were made. 
A possible explanation could be that site B has very specific interactions with the target and 
any modification that could alter the steric match between site B and the target would reduce 
the strength of the interaction. However, anti-viral activity was observed with compound 57, 
which has a chloro group in the 4-position of the phenyl ring at site B and an IC50 of 2.5 µM. 
When the chloro group was substituted with electron-donating groups, such as methoxy 
(compound 18) and methyl (compound 19), a decrease in activity was observed. This could 
suggest the presence of electronic effects.  
3.2.3. Interactions at site C 
The modifications at site C did not explore much of the SAR between NITD 10 and 
its target and were focused on identifying a linking site. With compound 25, it was designed 
to include a non-polar moiety, namely a t-butyl group, at site A in an attempt to utilize the 
favorable hydrophobic interactions to improve the overall binding affinity for the target. It has 
a desirable activity of an IC50 of 0.8 µM but once the primary amino group was acetylated, the 
activity was lost. Substitution of a primary amino group on the phenyl ring at site C is most 
optimal at the 5-position of the ring. However, when the primary amino group at 5-position 
was extended with a methylene group (compound 54), activity was lost. Similar to site B, this 
could indicate specific interactions that do not accommodate steric bulk.
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4. Conclusion 
In this study, an attempt was made to synthesize an immobilizable compound for the 
target identification of NITD10 using chemical proteomics. However, all analogs with the 
acetylated primary amino group incorporated did not have the desired activity in the CFI 
assay and thus, the chemical proteomics analysis was not carried out. Possible interactions for 
NITD10 with its target(s) were highlighted and the suitability of NITD10 as a tool compound 
for the target pull down experiment was questioned.  
Thirty-seven analogs were synthesized and even though an immobilizable compound 
was not found, a preliminary SAR was established. Site A proved to be most amendable to 
changes and analogs of NITD10 with improved activity have been found. On the other hand, 
sites B and C were less accommodating to modifications. These findings could provide useful 








5. Experimental Sections 
5.1. General Methods 
Materials and reagents used were of the highest commercially available grade and without 
further purification. 2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester and 
(E)-3-biphenyl-2-yl-acrylic acid were obtained from the chemical archive of NITD.  
Reactions requiring microwave irradiation were performed on a Biotage InitiatorTM 
microwave system with an operating frequency of 2.4 GHz. 
Thin layer chromatography (TLC) was carried out on Merck silica gel 60 F254 (2.5 × 7.5 cm) 
using UV light (λ = 254nm) for visualization. TLC data are given as the Rf value with the 
corresponding eluent system specified in brackets.  
1H NMR and 13C NMR spectra were determined on a Varian 300 Mercury spectrometer. 
Chemical shifts (δ) are expressed in ppm. Splitting patterns are described as singlet (s), broad 
singlet (br.s.), doublet (d), doublet of doublet (dd), doublet of doublet of doublet (ddd), 
doublet of triplet (dt), triplet (t) or multiplet (m). 
LC-MS analyses were performed with an Agilent LC1100 coupled with Applied Biosystems 
API2000, using the following conditions: monolithic-C18, 50 × 4.6 mm column; mobile 
system of acetonitrile/water with 0.1% of formic acid with a gradient of 5-95% acetonitrile; 
run time of 4 min; UV 254 and 214 nm; and flow rate of 3 mL/min.  
HPLC purity determinations were made on an Agilent LC1100 HPLC, using the following 
conditions: SymmetryShield RP-18 3.5µm, 150 × 4.6 mm column; mobile system of 
acetonitrile/water with 0.1% of formic acid with a gradient of 5-95% acetonitrile; run time of 
20 min; UV 254 and 214 nm; and flow rate of 0.8 mL/min. 
Flash chromatography was performed using a Teledyne ISCO CombiFlash® system using 
RediSep® Rf disposable Flash columns. HPLC purification was carried out on a Waters Prep 
LC with an Atlantis C18, 10µm, 19 × 250 mm column; mobile system of acetonitrile/water 
with 0.1% of formic acid; run time of 40 min; UV 254 and 214 nm; and flow rate of 20 
mL/min. 
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5.2. General Procedures 
5.2.1. General procedure for the Suzuki coupling of 2-[(E)-3-(2-bromo-phenyl)-
acryloylamino]-benzoic acid methyl ester with a boronic acid 
2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (1.0 eq), boronic acid 
(1.0 eq) and tetrakis(triphenylphosphine) palladium (0) (0.05 eq) were dissolved in dry 1,4-
dioxane (1 mL) to form a clear yellow solution. 1M Na2CO3 (3.0 eq) was subsequently added 
and the resulting mixture, with white precipitate, was subjected to microwave irradiation at 
130ºC for 30 minutes. Purification of the crude reaction mixture by HPLC yielded the benzoic 
acid. 
5.2.2. General procedure for esterification of benzoic acid 
Benzoic acid (1.0 eq) was dissolved in dry tetrahydrofuran and trimethylsilyl diazomethane 
(1.6 eq) and dry methanol were added subsequently. The reaction mixture was stirred at room 
temperature, under argon, to completion. A few drops of acetic acid were added to quench the 
reaction, which was further evaporated to give a crude mixture. Purification of the crude 
mixture by flash chromatography yielded the benzoic acid methyl ester.  
5.2.3. General procedure for reduction of a nitro group 
The nitro compound (1.0 eq) was dissolved in ethyl acetate (2.5 mL) and tin (II) chloride 
dihydrate (3.0-4.0 eq) was added subsequently. The resulting mixture was refluxed at 600C 
for 23 hours. Upon cooling, the reaction mixture was quenched with cold saturated sodium 
bicarbonate solution (30 mL) and extracted with ethyl acetate (3 x 20 mL) with solid sodium 
chloride added. The organic layers were combined, dried over sodium sulfate and 
concentrated. Purification of the crude mixture by HPLC yielded the reduced amino 
compound.  
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5.2.4. General procedure for Boc-deprotection 
The Boc-protected amine was added to a mixture of trifluoroacetic acid (TFA) (0.6 mL), 
dichloromethane (1.4 mL) and a few drops of water. The reaction mixture was stirred at room 
temperature for 1 hour. After the reaction mixture was concentrated, the residue was triturated 
with ether to obtain the TFA-salt.  
5.3. Synthesis of analogs of NITD10 





2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (86.5 mg, 0.24 mmol) 
was coupled with 4-tolylboronic acid (32.6 mg, 0.24 mmol) following the general procedure. 
The obtained bright yellow solution with black precipitate was filtered and purified by HPLC, 
eluting with acetonitrile (30-95%) in water. The title compound was isolated as a white solid 
(30.8 mg, 0.09 mmol, 36% yield). 
LC-MS: Rt 2.90 mins; m/z (ESI): [M+H]+ 358; [M-H]- 356.  
1H NMR (300 MHz, CDCl3-d): δ = 2.38 (s, 3H, CH3), 6.55 (d, J = 15.0 Hz, 1H, CH=CH), 
7.13 (dt, J = 6.3, 2.7 Hz, 1H, Ar-H), 7.26 (m, 1H, Ar-H), 7.38-7.47 (m, 6H, Ar-H), 7.61 (dt, J 
= 6.0, 2.4 Hz, 1H, Ar-H), 7.74-7.79 (m, 1H, Ar-H), 7.84 (d, J = 15.3, 1H, CH=CH), 8.13 (dd, 
J = 7.2, 2.7 Hz, 1H, Ar-H), 8.86 (dd, J = 9.0, 2.4 Hz, 1H, Ar-H), 11.12 (br.s., 1H, NH). 
13C NMR (75 MHz, CDCl3): δ = 21.31, 115.40, 121.04, 122.60, 123.06, 127.04, 127.61, 
129.29 (2C), 129.90 (2C), 129.99, 130.81, 132.08, 132.93, 135.82, 137.17, 137.56, 142.46, 
142.53, 143.36, 165.15, 172.36.  
Purity: >95% by HPLC. 






2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (80.0 mg, 0.22 mmol) 
was coupled with 4-tert-butylphenylboronic acid (39.5 mg, 0.22 mmol) following the general 
procedure. The obtained yellow solution with black precipitate was filtered and purified by 
HPLC, eluting with acetonitrile (30-95%) in water. The title compound was isolated as a 
white crystalline solid (49.3 mg, 0.12 mmol, 56% yield). 
LC-MS: Rt 3.26 mins; m/z (ESI): [M+H]+ 400; [M-H]- 398.  
1H NMR (300 MHz, CDCl3-d): δ = 1.36 (s, 9H, (CH3)3), 6.56 (d, J = 15.6 Hz, 1H, CH=CH), 
7.11 (dt, J = 7.2, 3.0 Hz, 1H, Ar-H), 7.25-7.30 (m, 2H, Ar-H), 7.35-7.47 (m, 5H, Ar-H), 7.58 
(dt, J = 6.0, 3.2 Hz, 1H, Ar-H), 7.74-7.78 (m, 1H, Ar-H), 7.87 (d, J = 15.3, 1H, CH=CH), 
8.12 (dd, J = 6.2, 3.0 Hz, 1H, Ar-H), 8.84 (dd, J = 9.0, 2.4 Hz, 1H, Ar-H), 11.10 (br.s., 1H, 
NH). 
Purity: >99% by HPLC. 









2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (60.0 mg, 0.17 mmol) 
was coupled with 3-trifluoromethylphenylboronic acid (31.6 mg, 0.17 mmol) following the 
general procedure. The obtained pale yellow solution with black precipitate was filtered and 
purified by HPLC, eluting with acetonitrile (30-95%) in water. The title compound was 
isolated as a white solid (32.8 mg, 0.08 mmol, 48% yield). 
LC-MS: Rt 2.93 mins; m/z (ESI): [M+H]+ 412; [M-H]- 410.  
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1H NMR (300 MHz, MeOD-d4): δ = 6.73 (d, J = 15.0Hz, 1H, CH=CH), 7.15 (dt, J = 6.0,  3.2 
Hz, 1H, Ar-H), 7.39-7.45 (m, 1H, Ar-H), 7.50-7.77 (m, 8H, Ar-H & CH=CH), 7.88-7.92 (m, 
1H, Ar-H), 8.11 (dd, J = 9.0, 3.0 Hz, 1H, Ar-H), 8.62 (dd, J = 9.0, 2.4 Hz, 1H, Ar-H). 
Purity: >99% by HPLC. 







2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (60.0 mg, 0.17 mmol) 
was coupled with 4-methoxybenzeneboronic acid (25.3 mg, 0.17 mmol) following the general 
procedure. The obtained pale yellow solution with black precipitate was filtered and purified 
by HPLC, eluting with acetonitrile (30-95%) in water. The title compound was isolated as a 
white solid (29.1 mg, 0.08 mmol, 47% yield). 
LC-MS: Rt 2.71 mins; m/z (ESI): [M+H]+ 374; [M-H]- 372.  
1H NMR (300 MHz, CDCl3-d): δ = 3.91 (s, 3H, O-CH3), 6.53 (d, J = 15.0Hz, 1H, CH=CH), 
6.93-6.97 (m, 2H, Ar-H), 7.11 (dt, J = 8.0, 1.2 Hz, 1H, Ar-H), 7.26-7.28 (m, 2H, Ar-H), 7.32-
7.42 (m, 3H, Ar-H), 7.58 (dt, J = 7.0, 2.0 Hz, 1H, Ar-H), 7.71-7.75 (m, 1H, Ar-H), 7.81 (d, J 
= 15.0Hz, 1H, CH=CH), 8.11 (dd, J = 9.0, 3.0 Hz, 1H, Ar-H), 8.84 (dd, J = 9.0, 2.4 Hz, 1H, 
Ar-H), 11.10 (br.s., 1H, NH). 
Purity: >95% by HPLC. 







2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (50.0 mg, 0.14 mmol) 
was coupled with 4-dimethylaminophenylboronic acid (22.9 mg, 0.14 mmol) following the 
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general procedure. The obtained bright orange yellow solution with black precipitate was 
filtered and purified by HPLC, eluting with acetonitrile (20-95%) in water. The title 
compound was isolated as a yellow solid (24.1 mg, 0.06 mmol, 45% yield). 
LC-MS: Rt 2.56 mins; m/z (ESI): [M+H]+ 387; [M-H]- 385.  
1H NMR (300 MHz, DMSO-d6): δ = 2.98 (s, 6H, N-(CH3)2), 6.77-6.85 (m, 3H, CH=CH & 
Ar-H), 7.12-7.19 (m, 3H, Ar-H), 7.33-7.49 (m, 3H, Ar-H), 7.58 (dt, J = 7.5, 2.7 Hz, 1H, Ar-
H), 7.67 (d, J = 14.4, 1H, CH=CH), 7.90 (dd, J = 8.1, 2.7 Hz, 1H, Ar-H), 8.00 (dd, J = 8.4, 
3.0 Hz, 1H, Ar-H), 8.55 (dd, J = 8.2, 2.7 Hz, 1H, Ar-H), 11.48 (br.s., 1H, NH). 
Purity: >95% by HPLC. 








2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (50.0 mg, 0.14 mmol) 
was coupled with 3,4-dimethoxyphenylboronic acid (25.3 mg, 0.14 mmol) following the 
general procedure. The obtained bright yellow solution with black precipitate was filtered and 
purified by HPLC, eluting with acetonitrile (30-95%) in water. The title compound was 
isolated as an off-white solid (29.6 mg, 0.07 mmol, 53% yield). 
LC-MS: Rt 2.55 mins; m/z (ESI): [M+H]+ 404; [M-H]- 402. 
1H NMR (300 MHz, CDCl3-d): δ = 3.86 (s, 3H, O-CH3), 3.91 (s, 3H, O-CH3), 6.54 (d, J = 
15.6 Hz, 1H, CH=CH), 6.85-6.95 (m, 3H, Ar-H), 7.10 (dt, J = 6.6, 2.7 Hz, 1H, Ar-H), 7.33-
7.44 (m, 3H, Ar-H), 7.58 (dt, J = 8.7, 3.0 Hz, 1H, Ar-H), 7.71-7.76 (m, 1H, Ar-H), 7.80 (d, J 
= 15.3 Hz, 1H, CH=CH), 8.09 (dd, J = 7.8, 1.5 Hz, 1H, Ar-H), 8.82 (dd, J = 9.0, 1.2 Hz, 1H, 
Ar-H), 11.19 (br.s., 1H, NH). 
Purity: >99% by HPLC. 









2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (50.0 mg, 0.14 mmol) 
was coupled with 4-trifluoromethylphenylboronic acid (26.4 mg, 0.14 mmol) following the 
general procedure. The obtained bright yellow solution with black precipitate was filtered and 
purified by HPLC, eluting with acetonitrile (30-95%) in water. The title compound was 
isolated as a white solid (45.0 mg, 0.11 mmol, 79% yield). 
LC-MS: Rt 2.98 mins; m/z (ESI): [M+H]+ 412; [M-H]- 410. 
1H NMR (300 MHz, MeOD-d4): δ = 6.75 (d, J = 14.4, 1H, CH=CH), 7.15 (dt, J = 6.9, 2.7 Hz, 
1H, Ar-H), 7.39-7.45 (m, 1H, Ar-H), 7.49-7.58 (m, 5H, Ar-H), 7.66 (d, J = 15.0 Hz, 1H, 
CH=CH), 7.77-7.82 (m, 2H, Ar-H), 7.89-7.93 (m, 1H, Ar-H), 8.11 (dd, J = 8.7, 1.5 Hz, 1H, 
Ar-H), 8.61 (dd, J = 7.8, 2.7 Hz, 1H, Ar-H). 
Purity: >99% by HPLC. 







2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (50.0 mg, 0.14 mmol) 
was coupled with 4-fluorophenylboronic acid (19.4 mg, 0.14 mmol) following the general 
procedure. The obtained yellow solution with black precipitate was filtered and purified by 
HPLC, eluting with acetonitrile (30-95%) in water. The title compound was isolated as a 
white solid (28.6 mg, 0.08 mmol, 57% yield). 
LC-MS: Rt 2.79 mins; m/z (ESI): [M+H]+ 362; [M-H]- 360. 
1H NMR (300 MHz, CDCl3-d): δ = 6.51 (d, J = 14.7 Hz, 1H, CH=CH), 7.01-7.12 (m, 3H, Ar-
H), 7.25-7.32 (m, 3H, Ar-H), 7.34-7.41 (m, 2H, Ar-H), 7.46-7.52 (m, 1H, Ar-H), 7.64-7.71 
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(m, 2H, CH=CH & Ar-H), 8.04 (dd, J = 9.0, 3.0 Hz, 1H, Ar-H), 8.71 (dd, J = 9.0, 2.4 Hz, 1H, 
Ar-H), 11.53 (br.s., 1H, NH). 
Purity: >98% by HPLC. 







2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (50.0 mg, 0.14 mmol) 
was coupled with 4-hydroxymethylphenylboronic acid (21.1 mg, 0.14 mmol) using the 
general procedure. The obtained yellow solution with black precipitate was filtered and 
purified by HPLC, eluting with acetonitrile (30-95%) in water. The title compound was 
isolated as a white solid (19.9 mg, 0.05 mmol, 38% yield). 
LC-MS: Rt 2.32 mins; m/z (ESI): [M-H]- 372. 
1H NMR (300 MHz, MeOD-d4): δ = 4.69 (s, 2H, CH2), 6.67 (d, J = 15.0 Hz, 1H, CH=CH), 
7.15 (dt, J = 9.0, 3.0 Hz, 1H, Ar-H), 7.31-7.58 (m, 8H, Ar-H), 7.73 (d, J = 15.3 Hz, 1H, 
CH=CH), 7.84-7.87 (m, 1H, Ar-H), 8.10 (dd, J = 9.0, 3.0 Hz, 1H, Ar-H), 8.62 (dd, J = 9.0, 
2.7 Hz, 1H, Ar-H). 
Purity: >98% by HPLC. 





2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (60.0 mg, 0.17 mmol) 
was coupled with 2-tolylboronic acid (22.7 mg, 0.17 mmol) using the general procedure. The 
obtained bright yellow solution with black precipitate was filtered and purified by HPLC, 
 76 
eluting with acetonitrile (30-95%) in water. The title compound was isolated as an off- white 
solid (22.8 mg, 0.06 mmol, 38% yield). 
LC-MS: Rt 2.90 mins; m/z (ESI): [M+H]+ 358; [M-H]- 356. 
1H NMR (300 MHz, MeOD-d4): δ = 2.05(s, 3H, CH3), 6.62 (d, J = 15.0 Hz, 1H, CH=CH), 
7.09-7.17 (m, 2H, Ar-H), 7.20-7.33 (m, 4H, Ar-H), 7.40-7.56 (m, 4H, Ar-H & CH=CH), 
7.87-7.91 (m, 1H, Ar-H), 8.09 (dd, J = 8.1, 3.0 Hz, 1H, Ar-H), 8.57 (dd, J = 8.4, 2.4 Hz, 1H, 
Ar-H). 
Purity: >98% by HPLC. 





2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (60.0 mg, 0.17 mmol) 
was coupled with 3-tolylboronic acid (22.7 mg, 0.17 mmol) using the general procedure. The 
obtained bright yellow solution with black precipitate was filtered and purified by HPLC, 
eluting with acetonitrile (30-95%) in water. The title compound was isolated as a white solid 
(41.7 mg, 0.12 mmol, 70% yield). 
LC-MS: Rt 2.94 mins; m/z (ESI): [M+H]+ 358; [M-H]- 356. 
1H NMR (300 MHz, MeOD-d4): δ = 2.41 (s, 3H, CH3), 6.67 (d, J = 15.6 Hz, 1H, CH=CH), 
7.09-7.25 (m, 4H, Ar-H), 7.42-7.58 (m, 5H, Ar-H), 7.73 (d, J = 15.0 Hz, 1H, CH=CH), 7.83-
7.87 (m, 1H, Ar-H), 8.10 (dd, J = 8.7, 2.4 Hz, 1H, Ar-H), 8.61 (dd, J = 8.7, 2.1 Hz, 1H, Ar-
H). 
Purity: >99% by HPLC. 








2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (80.0 mg, 0.22 mmol) 
was coupled with 3-amino-4-methylphenylboronic acid (33.5 mg, 0.22 mmol) according to 
the general procedure. The obtained brown yellow solution with black precipitate was filtered 
and purified by HPLC, eluting with acetonitrile (30-95%) in water. The title compound was 
isolated as a white solid (53.2 mg, 0.14 mmol, 72% yield). 
LC-MS: Rt 2.34 mins; m/z (ESI): [M+H]+ 373; [M-H]- 371. 
1H NMR (300 MHz, DMSO-d6): δ = 2.10 (s, 3H, CH3), 6.38 (dd, J = 6.6 Hz, 3.0Hz, 1H, Ar-
H), 6.55 (d, J = 2.1 Hz, 1H, Ar-H), 6.76 (d, J = 15.6 Hz, 1H, CH=CH), 6.99 (d, J = 8.7 Hz, 
1H, Ar-H), 7.11 (dt, J = 7.5, 3.0 Hz, 1H, Ar-H), 7.28 (dd, J = 6.3, 2.7 Hz, 1H, Ar-H), 7.36-
7.46 (m, 2H, Ar-H), 7.48-7.56 (m, 1H, Ar-H), 7.62 (d, J = 15.6 Hz, 1H, CH=CH), 7.89 (dd, J 
= 8.1, 2.1 Hz, 1H, Ar-H), 7.98 (dd, J = 7.5, 2.1 Hz, 1H, Ar-H), 8.52 (dd, J = 9.0, 1.5 Hz, 1H, 
Ar-H), 11.85 (br.s., 1H, NH). 
Purity: >99% by HPLC. 







3-Amino-4-methylphenylboronic acid (100.2 mg, 0.66 mmol) was dissolved in pyridine (3 
mL) to give a clear brown solution. Acetic anhydride (2 mL) and catalytic amount of 4-
dimethylaminopyridine were subsequently added. The reaction mixture was stirred at room 
temperature for 1 hr. Ethyl acetate (10 mL) was added and the organic layer was washed with 
1M hydrochloric acid (10 mL). The organic layer was dried over sodium sulfate and purified 
with HPLC, eluting with acetonitrile (0-50%) in water. The title compound was isolated as a 
white solid (42.7 mg, 0.22 mmol, 33% yield).  
LC-MS: Rt 0.86 mins; m/z (ESI): [M+H]+ 194; [M-H]- 192. 
1H NMR (300 MHz, MeOD-d4): δ = 2.15 (s, 3H, CH3), 2.24 (s, 3H, O=C-CH3), 7.17-7.66 (m, 
3H, Ar-H). 
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2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (69.1 mg, 0.19 mmol) 
was coupled with 3-acetylamino-4-methylphenylboronic acid 13a (37.0 mg, 0.19 mmol) 
according to the general procedure. The obtained dark brown yellow solution with black 
precipitate was filtered and purified by HPLC, eluting with acetonitrile (30-95%) in water. 
The title compound was isolated as a white solid (52.1 mg, 0.13 mmol, 66% yield). 
LC-MS: Rt 2.32 mins; m/z (ESI): [M+2H]+ 416; [M-H]- 413. 
1H NMR (300 MHz, DMSO-d6): δ = 2.08 (s, 3H, CH3), 2.28 (s, 3H, O=C-CH3), 6.82 (d, J = 
15.53 Hz, 1H, CH=CH), 7.01 (dd, J = 7.77, 1.61 Hz, 1H, Ar-H), 7.14 (ddd, J = 8.06, 7.18, 
1.17 Hz, 1H, Ar-H), 7.29-7.36 (m, 2H, Ar-H), 7.41-7.61 (m, 5H, Ar-H & CH=CH), 7.95 (dd, 
J = 7.62, 1.76 Hz, 1H, Ar-H), 7.99 (dd, J = 7.91, 1.47 Hz, 1H, Ar-H), 8.52 (dd, J = 8.50, 0.88 
Hz, 1H, Ar-H), 9.50 (br.s., 1H, NH), 11.65 (br.s., 1H, NH). 
Purity: >99% by HPLC. 





2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (60.0 mg, 0.17 mmol) 
was coupled with 4-butylphenyl boronic acid (29.7 mg, 0.17 mmol) according to the general 
procedure. The obtained pale green yellow solution with black precipitate was filtered and 
purified by HPLC, eluting with acetonitrile (50-95%) in water. The title compound was 
isolated as a white solid (44.5 mg, 0.11 mmol, 67% yield). 
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LC-MS: Rt 3.40 mins; m/z (ESI): [M-H]- 398. 
1H NMR (300 MHz, CDCl3-d): δ = 0.97 (t, J = 7.33 Hz, 3H, CH3), 1.35-1.49 (m, 2H, CH2), 
1.60-1.73 (m, 2H, CH2), 2.66 (t, J = 7.62 Hz, 2H, CH2), 6.58 (d, J = 15.53 Hz, 1H, CH=CH), 
7.15 (ddd, J = 8.06, 7.18, 1.17 Hz, 1H, Ar-H), 7.29 (s, 4H, Ar-H),  7.36-7.48 (m, 3H, Ar-H), 
7.62 (ddd, J = 8.57, 7.25, 1.76 Hz, 1H, Ar-H), 7.75-7.80 (m, 1H, Ar-H), 7.88 (d, J = 15.53 
Hz, 1H, CH=CH), 8.15 (dd, J = 8.20, 1.47 Hz, 1H, Ar-H), 8.87 (dd, J = 8.50, 0.88 Hz, 1H, 
Ar-H), 11.18 (br.s., 1H, NH). 
Purity: >99% by HPLC. 





2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (60.0 mg, 0.17 mmol) 
was coupled with 2,6-dimethylphenylboronic acid (25.0 mg, 0.17 mmol) according to the 
general procedure. The obtained clear yellow solution with white precipitate was filtered and 
purified by HPLC, eluting with acetonitrile (50-95%) in water. The title compound was 
isolated as a white solid (29.5 mg, 0.08 mmol, 48% yield). 
LC-MS: Rt 2.97 mins; m/z (ESI): [M-H]- 370. 
1H NMR (300 MHz, CDCl3-d): δ = 1.95 (s, 6H, CH3 & CH3), 6.37 (d, J = 15.53 Hz, 1H, 
CH=CH), 7.08-7.24 (m, 5H, Ar-H), 7.37-7.49 (m, 3H, Ar-H & CH=CH), 7.58 (ddd, J = 8.64, 
7.33, 1.61 Hz, 1H, Ar-H), 7.80 (dd, J = 7.47, 1.61 Hz, 1H, Ar-H), 8.12 (dd, J = 7.91, 1.47 Hz, 
1H, Ar-H), 8.81 (dd, J = 8.50, 0.88 Hz, 1H, Ar-H), 11.03 (br.s., 1H, NH). 
Purity: >99% by HPLC. 








2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (60.0 mg, 0.17 mmol) 
was coupled with 4-nitrophenylboronic acid (27.9 mg, 0.17 mmol) according to the general 
procedure. The obtained dark yellow solution with black precipitate was filtered and purified 
by HPLC, eluting with acetonitrile (30-95%) in water. The title compound was isolated as a 
white solid (30.1 mg, 0.08 mmol, 46% yield). 
LC-MS: Rt 2.74 mins; m/z (ESI): [M+H]+ 389; [M-H]- 387. 
1H NMR (300 MHz, DMSO-d6): δ = 6.88 (d, J = 15.53 Hz, 1H, CH=CH), 7.12-7.18 (m, 1H, 
Ar-H), 7.43-7.60 (m, 5H, Ar-H & CH=CH), 7.62-7.68 (m, 2H, Ar-H), 7.97-8.05 (m, 2H, Ar-
H), 8.38 (m, 2H, Ar-H), 8.52 (d, J = 8.20 Hz, 1H, Ar-H), 11.70 (br.s., 1H, NH). 
Purity: >99% by HPLC. 









2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (60.0 mg, 0.17 mmol) 
was coupled with 3-(boc-amino)phenylboronic acid (39.6 mg, 0.17 mmol) according to the 
general procedure. The obtained dark greenish yellow solution with black precipitate was 
filtered and purified by HPLC, eluting with acetonitrile (50-95%) in water. The title 
compound was isolated as a white solid (57.4 mg, 0.13 mmol, 75% yield). 
LC-MS: Rt 2.91 mins; m/z (ESI): [M-H]- 457. 
1H NMR (300 MHz, CDCl3-d): δ = 1.60 (s, 9H, (CH3)3), 6.67 (d, J = 17.00 Hz, 1H, CH=CH), 
7.05-7.13 (m, 3H, Ar-H), 7.35-7.46 (m, 4H, Ar-H), 7.53-7.65 (m, 3H, Ar-H & CH=CH), 7.80 
(d, J = 7.33 Hz, 1H, Ar-H), 8.11 (d, J = 8.20 Hz, 1H, Ar-H), 8.79 (dd, J = 8.50, 1.17 Hz, 1H, 
Ar-H), 11.71 (br.s., 1H, NH). 
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Purity: >95% by HPLC. 




According to the general procedure, 4-methoxyanthranilic acid (60.0 mg, 0.36 mmol), 
dissolved in dry tetrahydrofuran (1.25 mL), was esterified with trimethylsilyl diazomethane 
(0.29 ml, 0.57 mmol) with dry methanol (0.14 mL) added. The clear brown solution obtained 
was purified by flash chromatography (hexanes:ethyl acetate 9:1). The title compound was 
obtained as a white solid (34.5 mg, 0.19 mmol, 53% yield). 
TLC: Rf = 0.5 (hexanes:ethyl acetate 2:1). 
LC-MS: Rt 1.91 mins; m/z (ESI): [M-H]- 180. 
1H NMR (300 MHz, MeOD-d4): δ = 3.77 (s, 3H, CH3), 3.80 (s, 3H, CH3), 6.17 (dd, J = 9.08, 
2.64 Hz, 1H, Ar-H), 6.24 (d, J = 2.34 Hz, 1H, Ar-H), 7.70 (d, J = 8.79 Hz, 1H, Ar-H). 







(E)-3-Biphenyl-2-yl-acrylic acid (21.5 mg, 0.10 mmol) was dissolved in dichloromethane (3 
mL) and cooled on ice. Thionyl chloride (0.11 mL, 1.44 mmol) was added and the resulting 
solution was heated to reflux at 50ºC for 2 hours. The reaction mixture was concentrated and 
re-dissolved in dimethylformamide (1.5 mL). 2-Amino-4-methoxy benzoic acid methyl ester 
18a (23.3 mg, 0.10 mmol) dissolved in dimethylformamide (1 mL) was added to the reaction 
mixture. Pyridine (9.1 µL, 0.11 mmol) and catalytic amounts of dimethylaminopyridine were 
added and the resulting mixture was subjected to microwave irradiation at 130ºC for 6 hours. 
The reaction did not run to completion but was stopped when about 50% of title compound 
was formed. The obtained mixture was purified by HPLC, eluting with acetonitrile (30-95%) 
in water. The title compound was isolated as a white solid (15.0 mg, 0.04 mmol, 42% yield). 
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LC-MS: Rt 2.85 mins; m/z (ESI): [M+H]+ 374; [M-H]- 372. 
1H NMR (300 MHz, CDCl3-d): δ = 3.89 (s, 3H, O-CH3), 6.55 (d, J = 15.53 Hz, 1H, CH=CH), 
6.65 (dd, J = 8.94, 2.49 Hz, 1H, Ar-H), 7.33-7.49 (m, 8H, Ar-H), 7.76-7.79 (m, 1H, Ar-H), 
7.82 (d, J = 15.53 Hz, 1H, CH=CH), 8.04 (d, J = 9.08 Hz, 1H, Ar-H), 8.53 (d, J = 2.64 Hz, 
1H, Ar-H), 11.38 (br.s., 1H, NH). 
Purity: >99% by HPLC. 




According to the general procedure, 2-amino-4-methyl benzoic acid (60.0 mg, 0.40 mmol), 
dissolved in dry tetrahydrofuran (1.25 mL), was esterified with trimethylsilyl diazomethane 
(0.32 ml, 0.64 mmol) with dry methanol (0.14 mL) added. The brown yellow solution 
obtained was purified by flash chromatography (hexanes:ethyl acetate 6:1). The title 
compound was obtained as a white crystalline solid (44.3 mg, 0.27 mmol, 68% yield). 
TLC: Rf = 0.12 (hexanes:ethyl acetate 9:1). 
LC-MS: Rt 1.30 mins; m/z (ESI): [M+H]+ 166; [M-H]- 164. 
1H NMR (300 MHz, CDCl3-d): δ = 2.20 (s, 3H, CH3), 3.88 (s, 3H, O-CH3), 7.11 (d, J = 7.62 
Hz, 1H, Ar-H), 7.34-7.40 (m, 2H, Ar-H). 





(E)-3-Biphenyl-2-yl-acrylic acid (80.0 mg, 0.36 mmol) was dissolved in dichloromethane (11 
mL) and cooled on ice. Thionyl chloride (0.39 mL, 5.36 mmol) was added and the resulting 
solution was heated to reflux at 50ºC for 3 hours 45 minutes. The reaction mixture was 
concentrated and re-dissolved in dimethylformamide (5 mL). 2-Amino-4-methyl benzoic acid 
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methyl ester 19a (59.0 mg, 0.36 mmol), pyridine (33.8 µL, 0.42 mmol) and catalytic amounts 
of dimethylaminopyridine were subsequently added and the resulting mixture was subjected 
to microwave irradiation at 130ºC for 7 hours. The obtained pale yellow brown mixture was 
purified by HPLC, eluting with acetonitrile (30-95%) in water. The title compound was 
isolated as a white crystalline solid (43.8 mg, 0.12 mmol, 33% yield). 
LC-MS: Rt 2.86 mins; m/z (ESI): [M+H]+ 372; [M-H]- 370. 
1H NMR (300 MHz, CDCl3-d): δ = 2.33 (s, 3H, CH3), 3.89 (s, 3H, O-CH3), 6.50 (d, J = 15.53 
Hz, 1H, CH=CH), 7.07 (s, 1H, Ar-H), 7.28 (d, J = 7.91 Hz, 1H, Ar-H), 7.32-7.49 (m, 8H, Ar-
H), 7.70-7.81 (m, 2H, Ar-H), 7.79 (d, J = 15.53 Hz, 1H, CH=CH), 8.57 (br.s., 1H, NH). 





2-[(E)-3-Biphenyl-2-yl-acryloylamino]-4-methyl-benzoic acid methyl ester 19b (32.0 mg, 
0.09 mmol) was dissolved in tetrahydrofuran (2.5 mL). 4M lithium hydroxide (0.83 mL, 3.33 
mmol) was added and the reaction mixture was stirred at room temperature for 72 hours. The 
reaction did not run to completion but was stopped when about 60% of title compound were 
formed. After tetrahydrofuran was removed under reduced pressure, water (1 mL) was added. 
The aqueous layer was acidified using 3N hydrochloric acid and extracted with ethyl acetate 
(3 x 5 mL). The organic layers were collected, dried over sodium sulfate and concentrated. 
The crude reaction mixture was purified by HPLC, eluting with acetonitrile (40-95%) in 
water. The title compound was isolated as a white solid (15.6 mg, 0.04 mmol, 51% yield). 
LC-MS: Rt 2.51 mins; m/z (ESI): [M+H]+ 358; [M-H]- 356. 
1H NMR (300 MHz, DMSO-d6): δ = 2.31 (s, 3H, CH3), 7.02 (d, J = 15.53 Hz, 1H, CH=CH), 
7.31-7.56 (m, 10H, Ar-H & CH=CH), 7.63 (dd, J = 7.62, 1.76 Hz, 1H, Ar-H), 7.81-7.85 (m, 
1H, Ar-H), 8.22 (d, J = 1.47 Hz, 1H, Ar-H), 9.57 (br.s., 1H, NH). 
Purity: >95% by HPLC. 
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According to the general procedure, 2-amino-6-methyl benzoic acid (150.0 mg, 0.99 mmol), 
dissolved in dry tetrahydrofuran (3.2 mL), was esterified with trimethylsilyl diazomethane 
(0.79 ml, 1.59 mmol) with dry methanol (0.35 mL) added. The pale brown yellow solution 
obtained was purified by flash chromatography (hexanes:ethyl acetate 6:1). The title 
compound was obtained as a clear oil (129.9 mg, 0.79 mmol, 79% yield). 
TLC: Rf = 0.12 (hexanes:ethyl acetate 8:1). 
LC-MS: Rt 1.77 mins; m/z (ESI): [M+H]+ 166.  
1H NMR (300 MHz, MeOD-d4): δ = 2.36 (s, 3H, CH3), 3.87 (s, 3H, O-CH3), 6.48 (dd, J = 
7.03, 1.47 Hz, 1H, Ar-H), 6.61 (dd, J = 8.50, 0.59 Hz, 1H, Ar-H), 7.04 (t, J = 7.62 Hz, 1H, 
Ar-H). 





(E)-3-Biphenyl-2-yl-acrylic acid (171.0 mg, 0.76 mmol) was dissolved in dichloromethane 
(20 mL) and cooled on ice. Thionyl chloride (0.84 mL, 11.45 mmol) was added and the 
resulting solution was heated to reflux at 50ºC for 5 hours. The completed reaction was 
concentrated and re-dissolved in dimethylformamide (2.5 mL). A solution of 2-amino-6-
methyl benzoic acid methyl ester 20a (126.0 mg, 0.76 mmol) in dimethylformamide (2.5 
mL), pyridine (72.2 µL, 0.89 mmol) and catalytic amounts of dimethylaminopyridine were 
subsequently added and the resulting mixture was subjected to microwave irradiation at 
130ºC for 6 hours. The obtained pale brown mixture was purified by HPLC, eluting with 
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acetonitrile (40-95%) in water. The title compound was isolated as a pale yellow solid (45.6 
mg, 0.13 mmol, 17% yield). 
LC-MS: Rt 2.63 mins; m/z (ESI): [M+H]+ 358; [M-H]- 356. 
1H NMR (300 MHz, CDCl3-d): δ = 2.56 (s, 3H, CH3), 6.50 (d, J = 15.82 Hz, 1H, CH=CH), 
7.01 (d, J = 7.33 Hz, 1H, Ar-H), 7.31-7.47 (m, 9H, Ar-H), 7.70-7.75 (m, 1H, Ar-H), 7.78 (d, J 
= 15.53 Hz, 1H, CH=CH),  8.38 (d, J = 8.50 Hz, 1H, Ar-H), 10.11 (br.s., 1H, NH). 
Purity: >95% by HPLC. 




According to the general procedure, 2-amino-5-methyl benzoic acid (150.0 mg, 0.99 mmol), 
dissolved in dry tetrahydrofuran (3.2 mL), was esterified with trimethylsilyl diazomethane 
(0.79 ml, 1.59 mmol) with dry methanol (0.35 mL) added. The pale brown yellow solution 
obtained was purified by flash chromatography (hexanes:ethyl acetate 9:1). The title 
compound was obtained as a pale yellow crystalline solid  (153.9 mg, 0.93 mmol, 94% yield). 
TLC: Rf = 0.43 (hexanes:ethyl acetate 4:1). 
LC-MS: Rt 2.05 mins; m/z (ESI): [M+H]+ 166.  
1H NMR (300 MHz, MeOD-d4): δ = 2.19 (s, 3H, CH3), 3.84 (s, 3H, O-CH3), 6.67 (d, J = 8.50 
Hz, 1H, Ar-H), 7.06-7.10 (m, 1H, Ar-H), 7.58-7.60 (m, 1H, Ar-H). 





(E)-3-Biphenyl-2-yl-acrylic acid (153.4.0 mg, 0.68 mmol) was dissolved in dichloromethane 
(8 mL) and cooled on ice. Thionyl chloride (0.75 mL, 10.26 mmol) was added and the 
resulting solution was heated to reflux at 50ºC for 2 hours. The reaction mixture was 
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concentrated and re-dissolved in dimethylformamide (5 mL). 2-Amino-5-methyl benzoic acid 
methyl ester 21a (113.0 mg, 0.68 mmol), pyridine (64.7 µL, 0.80 mmol) and catalytic 
amounts of dimethylaminopyridine were subsequently added and the resulting mixture was 
subjected to microwave irradiation at 130ºC for 5 hours 30 minutes. The obtained brown 
mixture was purified by HPLC, eluting with acetonitrile (30-95%) in water. The title 
compound was isolated as an off-white solid (21.6 mg, 0.06 mmol, 9% yield). 
LC-MS: Rt 2.63 mins; m/z (ESI): [M-H]- 356. 
1H NMR (300 MHz, MeOD-d4): δ = 2.33 (s, 3H, CH3), 6.64 (d, J = 15.53 Hz, 1H, CH=CH), 
7.30-7.48 (m, 9H, Ar-H), 7.71 (d, J = 15.82 Hz, 1H, CH=CH), 7.80-7.84 (m, 1H, Ar-H), 7.91 
(d, J = 2.34 Hz, 1H, Ar-H), 8.48 (d, J = 8.50 Hz, 1H, Ar-H). 
Purity: >95% by HPLC. 






Methyl diethyl phosphonoacetate (0.33 mL, 1.83 mmol) was dissolved in anhydrous 
tetrahydrofuran (4 mL) and cooled to -78ºC under argon. Butyllithium (1.14 mL, 1.83 mmol) 
was then slowly added over 10 minutes and the resulting solution was stirred for 5 minutes. 
The solution was transferred to an ice bath and stirred for another 30 minutes. A solution of 2-
bromo-4-nitrobenzaldehyde (300.0 mg, 1.30 mmol) in dry tetrahydrofuran (4 mL) was added 
to the final reaction mixture, which was stirred for 5 hours. The reaction mixture was 
quenched with saturated ammonium chloride (30 mL) and extracted with ethyl acetate (3 x 25 
mL). The combined organic layers were dried over sodium sulfate and concentrated. The 
crude reaction mixture was purified by flash chromatography (hexanes:ethyl acetate 9:1). The 
title compound was obtained as a pale yellow solid (305.6 mg, 1.07 mmol, 82% yield). 
TLC: Rf = 0.37 (hexanes:ethyl acetate 8:1). 
LC-MS: Rt 2.52 mins; m/z (ESI): [M+H]+ 287.  
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1H NMR (300 MHz, CDCl3-d): δ = 3.86 (s, 3H, O-CH3), 6.51 (d, J = 16.12 Hz, 1H, CH=CH), 
7.75 (d, J = 8.50 Hz, 1H, Ar-H), 8.03 (d, J = 16.12 Hz, 1H, CH=CH), 8.20 (ddd, J = 8.64, 
1.17, 1.03 Hz, 1H, Ar-H), 8.50 (d, J = 2.34 Hz, 1H, Ar-H). 






(E)-3-(2-Bromo-4-nitro-phenyl)-acrylic acid methyl ester 22a (305.6.0 mg, 1.07 mmol) was 
dissolved in tetrahydrofuran (2.8 mL). 4M lithium hydroxide (0.94 mL, 3.74 mmol) was 
added and the reaction mixture was subjected to microwave irradiation at 65ºC for 1 hour. 
After tetrahydrofuran was removed under reduced pressure, water (10 mL) was added. The 
aqueous layer was acidified using 3N hydrochloric acid resulting in an orange precipitate. 
Filtration of the precipitate yielded the title compound as an orange solid (210.4 mg, 0.77 
mmol, 72% yield). 
LC-MS: Rt 2.05 mins; m/z (ESI): [M-H]- 271. 
1H NMR (300 MHz, MeOD-d4): δ = 6.65 (d, J = 15.82 Hz, 1H, CH=CH), 7.98-8.05 (m, 2H, 
Ar-H & CH=CH), 8.23 (dd, J = 2.34, 0.59 Hz, 1H, Ar-H), 8.52 (d, J = 2.34 Hz, 1H, Ar-H). 






O O  
(E)-3-(2-Bromo-4-nitro-phenyl)-acrylic acid 22b (210.4 mg, 0.77 mmol) was dissolved in 
dichloromethane (4 mL) and cooled on ice. Thionyl chloride (0.85 mL, 11.6 mmol) was 
added and the resulting solution was heated to reflux at 50ºC for 2 hours 20 minutes. The 
reaction mixture was concentrated and re-dissolved in dichloromethane (3 mL). Methyl 
anthranilate (100.0 µL, 0.77 mmol), pyridine (75.0 µL, 0.93 mmol) and catalytic amounts of 
dimethylaminopyridine were subsequently added and the resulting mixture was stirred at 
room temperature for 20 hours 30 minutes. Dichloromethane (20 mL) was added to the 
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reaction mixture and the organic layer was washed with 1M hydrochloric acid (2 x 20 mL), 
dried over sodium sulfate and concentrated. The crude orange solid was purified by flash 
chromatography (eluent system of hexanes:ethyl acetate 4:1). The title compound was 
obtained as a bright yellow solid (189.2 mg, 0.47 mmol, 60% yield). 
TLC: Rf = 0.68 (hexanes:ethyl acetate 1:1). 
LC-MS: Rt 2.98 mins; m/z (ESI): [M+H]+ 406; [M-H]- 404. 
1H NMR (300 MHz, CDCl3-d): δ = 3.97 (s, 3H, O-CH3), 6.70 (d, J = 15.53 Hz, 1H, CH=CH), 
7.13-7.19 (m, 1H, Ar-H), 7.62 (ddd, J = 8.64, 7.18, 1.76 Hz, 1H, Ar-H), 7.82 (d, J = 8.79 Hz, 
1H, Ar-H), 8.07-8.12 (m, 1H, Ar-H), 8.11 (d, J = 15.82 Hz, 1H, CH=CH), 8.21 (ddd, J = 
8.79, 2.34, 0.59 Hz, 1H, Ar-H), 8.51 (d, J = 2.05 Hz, 1H, Ar-H), 8.88 (dd, J = 8.64, 1.03 Hz, 
1H, Ar-H), 11.58 (br.s., 1H, NH). 





2-[(E)-3-(2-Bromo-4-nitro-phenyl)-acryloylamino]-benzoic acid methyl ester 22c (79.3 mg, 
0.20 mmol) was coupled with phenylboronic acid (23.9 mg, 0.20 mmol) following the general 
procedure. The obtained brown red solution with black precipitate was filtered and purified 
by HPLC, eluting with acetonitrile (30-95%) in water. The title compound was isolated as a 
white solid (53.0 mg, 0.14 mmol, 70% yield). 
LC-MS: Rt 2.83 mins; m/z (ESI): [M-H]- 387.  
1H NMR (300 MHz, MeOD-d4): δ = 6.83 (d, J = 15.53 Hz, 1H, CH=CH), 7.10-7.17 (m, 1H, 
Ar-H), 7.36-7.41 (m, 2H, Ar-H), 7.45-7.56 (m, 4H, Ar-H), 7.70 (d, J = 15.53 Hz, 1H, 
CH=CH), 8.03 (d, J = 8.50 Hz, 1H, Ar-H), 8.10 (dd, J = 7.91, 1.76 Hz, 1H, Ar-H), 8.21 (d, J 
= 2.05 Hz, 1H, Ar-H), 8.24-8.28 (m, 1H, Ar-H), 8.62 (dd, J = 8.50, 0.88 Hz, 1H, Ar-H). 
Purity: >98% by HPLC. 






2-[(E)-3-(2-Bromo-4-nitro-phenyl)-acryloylamino]-benzoic acid methyl ester 22c (68.4 mg, 
0.17 mmol) was coupled with 4-tert-butylphenylboronic acid (30.1 mg, 0.17 mmol) following 
the general procedure. The obtained brown red solution with black precipitate was filtered 
and purified by HPLC, eluting with acetonitrile (50-95%) in water. The title compound was 
isolated as a pale brown solid (47.4 mg, 0.11 mmol, 63% yield). 
LC-MS: Rt 2.83 mins; m/z (ESI): [M+H]+ 445; [M-H]- 443. 
1H NMR (300 MHz, CDCl3-d): δ = 6.69 (d, J = 15.53 Hz, 1H, CH=CH), 7.14-7.20 (m, 1H, 
Ar-H), 7.29-7.34 (m, 2H, Ar-H), 7.49-7.54 (m, 2H, Ar-H), 7.63 (ddd, J = 8.64, 7.18, 1.76 Hz, 
1H, Ar-H), 7.86 (d, J = 9.67 Hz, 1H, CH=CH), 7.90 (d, J = 2.93 Hz, 1H, Ar-H), 8.14 (dd, J = 
7.91, 1.47 Hz, 1H, Ar-H), 8.22 (dd, J = 8.79, 2.64 Hz, 1H, Ar-H), 8.27 (d, J = 2.05 Hz, 1H, 
Ar-H), 8.84 (dd, J = 8.50, 0.88 Hz, 1H, Ar-H), 11.29 (br.s., 1H, NH). 
Purity: >99% by HPLC. 





2-[(E)-3-(5-Nitro-biphenyl-2-yl)-acryloylamino]-benzoic acid 22 (43.3 mg, 0.11 mmol) was 
reduced following the general procedure. The crude reaction mixture was purified by HPLC, 
eluting with acetonitrile (30-95%) in water. The title compound was isolated as a white solid 
(12.8 mg, 0.04 mmol, 32% yield). 
LC-MS: Rt 2.39 mins; m/z (ESI): [M+H]+ 359; [M-H]- 357.  
1H NMR (300 MHz, MeOD-d4): δ = 6.42 (d, J = 15.24 Hz, 1H, CH=CH), 6.63 (d, J = 2.34 
Hz, 1H, Ar-H), 6.74 (dd, J = 8.79, 2.64 Hz, 1H, Ar-H), 7.07-7.14 (m, 1H, Ar-H), 7.29-7.55 
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(m, 6H, Ar-H & CH=CH), 7.61-7.68 (m, 2H, Ar-H), 8.08 (dd, J = 8.06, 1.32 Hz, 1H, Ar-H), 
8.59 (dd, J = 8.50, 0.88 Hz, 1H, Ar-H). 
Purity: >98% by HPLC. 





2-[(E)-3-(4’-tert-Butyl-5-nitro-biphenyl-2-yl)-acryloylamino]-benzoic acid 23 (38.4 mg, 0.09 
mmol) was reduced to following the general procedure. The crude reaction mixture was 
purified by HPLC, eluting with acetonitrile (50-95%) in water. The title compound was 
isolated as a yellow solid (22.5 mg, 0.05 mmol, 63% yield). 
LC-MS: Rt 2.89 mins; m/z (ESI): [M+H]+ 415; [M-H]- 413.  
1H NMR (300 MHz, CDCl3-d): δ = 1.36 (s, 9H, (CH3)3), 6.41 (d, J = 15.24 Hz, 1H, CH=CH), 
6.64-6.72 (m, 2H, Ar-H), 7.10 (ddd, J = 8.28, 7.25, 1.17 Hz, 1H, Ar-H), 7.25-7.30 (m, 2H, 
Ar-H), 7.41-7.46 (m, 2H, Ar-H), 7.58 (ddd, J = 8.64, 7.33, 1.61 Hz, 1H), 7.64 (d, J = 8.50 Hz, 
1H, Ar-H), 7.81 (d, J = 15.24 Hz, 1H, CH=CH), 8.11 (dd, J = 8.06, 1.32 Hz, 1H, Ar-H), 8.85 
(dd, J = 8.50, 0.88 Hz, 1H, Ar-H), 11.05 (br.s., 1H, NH).  
Purity: >99% by HPLC. 






According to the general procedure, 3-amino-4-methoxy benzoic acid (160.0 mg, 0.96 mmol), 
dissolved in dry tetrahydrofuran (3.2 mL), was esterified with trimethylsilyl diazomethane 
(077 ml, 1.53 mmol) with dry methanol (0.35 mL) added. The brown solution obtained was 
purified by flash chromatography (hexanes:ethyl acetate 4:1). The title compound was 
obtained as an off-white solid (137.6 mg, 0.76 mmol, 79% yield). 
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TLC: Rf = 0.21 (hexanes:ethyl acetate 4:1). 
LC-MS: Rt 1.12 mins; m/z (ESI): [M+H]+ 182. 
1H NMR (300 MHz, MeOD-d4): δ = 3.83 (s, 3H, CO2CH3), 3.91 (s, 3H, O-CH3), 6.89 (d, J = 
7.91 Hz, 1H, Ar-H), 7.38-7.40 (m, 1H, Ar-H) 7.42 (d, J = 2.05 Hz, 1H, Ar-H). 








(E)-3-Biphenyl-2-yl-acrylic acid (168.0 mg, 0.75 mmol) was dissolved in dichloromethane 
(10 mL) and cooled on ice. Thionyl chloride (0.82 mL, 11.24 mmol) was added and the 
resulting solution was heated to reflux at 50ºC for 1 hour 20 minutes. The reaction mixture 
was concentrated and re-dissolved in dimethylformamide (2.5 mL). A solution of 3-amino-4-
methoxy benzoic acid methyl ester 26a (135.6.0 mg, 0.75 mmol) in dimethylformamide (2.5 
mL), pyridine (70.9 µL, 0.88 mmol) and catalytic amounts of dimethylaminopyridine were 
added and the resulting mixture was subjected to microwave irradiation at 130ºC for 4 hours 
30 minutes. The obtained mixture was purified by HPLC, eluting with acetonitrile (40-95%) 
in water. The title compound was isolated as an off-white solid (39.9 mg, 0.10 mmol, 14% 
yield). 
LC-MS: Rt 2.94 mins; m/z (ESI): [M+H]+ 388; [M-H]- 386. 
1H NMR (300 MHz, CDCl3-d): δ = 3.87 (s, 3H, CO2CH3), 3.97 (s, 3H, O-CH3), 6.54 (d, J = 
15.53 Hz, 1H, CH=CH), 6.93 (d, J = 8.50 Hz, 1H, Ar-H), 7.32-7.49 (m, 8H, Ar-H & 
CH=CH), 7.73-7.78 (m, 1H, Ar-H), 7.80-7.82 (m, 1H, Ar-H), 7.84 (d, J = 2.05 Hz, 1H, Ar-
H), 7.88 (br.s., 1H, NH), 9.11 (d, J = 2.05 Hz, 1H, Ar-H).  









3-[(E)-3-Biphenyl-2-yl-acryloylamino]-4-methoxy-benzoic acid methyl ester 26b (37.9 mg, 
0.10 mmol) was dissolved in tetrahydrofuran (0.74 mL). 4M lithium hydroxide (0.25 mL, 
0.10 mmol) was added and the reaction mixture was subjected to microwave irradiation at 
65ºC for 3 hours 30 minutes. The reaction did not go to completion but was stopped when 
about 80% of title compound was formed. After tetrahydrofuran was removed under reduced 
pressure, water (5 mL) was added. The aqueous layer was acidified using 3N hydrochloric 
acid and extracted with ethyl acetate (3 x 15 mL). The combined organic layers were dried 
over sodium sulfate and concentrated. The crude reaction mixture was purified by HPLC, 
eluting with acetonitrile (40-95%) in water. The title compound was isolated as a white solid 
(26.7 mg, 0.07 mmol, 73% yield). 
LC-MS: Rt 2.58 mins; m/z (ESI): [M+H]+ 374; [M-H]- 372. 
1H NMR (300 MHz, DMSO-d6): δ = 3.93 (s, 3H, O-CH3), 7.13 (d, J = 8.79 Hz, 1H, Ar-H), 
7.22 (d, J = 15.53, 1H, CH=CH), 7.33 (dd, J = 8.20, 1.76 Hz, 1H, Ar-H), 7.36-7.54 (m, 8H, 
Ar-H & CH=CH), 7.69 (dd, J = 8.50, 2.34 Hz, 1H, Ar-H), 7.81-7.85 (m, 1H, Ar-H), 8.72 (t, J 
= 5.27, 2.64 Hz, 1H, Ar-H), 9.45 (br.s., 1H, NH). 
Purity: >99% by HPLC. 








(E)-3-Biphenyl-2-yl-acrylic acid (300.0 mg, 1.34 mmol) was dissolved in dichloromethane 
(18 mL) and cooled on ice. Thionyl chloride (1.47 mL, 20.1 mmol) was added and the 
resulting solution was heated to reflux at 50ºC for 2 hours 35 minutes. The reaction mixture 
was concentrated and re-dissolved in dimethylformamide (5 mL). Methyl-3-amino-4-
nitrobenzoate (262.9 mg, 1.34 mmol), pyridine (0.13 mL, 1.57 mmol) and catalytic amounts 
of dimethylaminopyridine were added and the resulting mixture was subjected to microwave 
irradiation at 130ºC for 5 hours. The obtained mixture was purified by HPLC, eluting with 
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acetonitrile (50-95%) in water. The title compound was isolated as a yellow solid (262.8 mg, 
0.68 mmol, 50% yield). 
LC-MS: Rt 2.72 mins; m/z (ESI): [M+H]+ 389; [M-H]- 387. 
1H NMR (300 MHz, MeOD-d4): δ = 6.82 (d, J = 15.53 Hz, 1H, CH=CH), 7.31-7.51 (m, 8H, 
Ar-H), 7.76 (d, J = 15.53 Hz, 1H, CH=CH), 7.86-7.93 (m, 2H, Ar-H), 8.15 (d, J = 9.08 Hz, 
1H, Ar-H), 8.74 (d, J = 1.76 Hz, 1H, Ar-H). 
Purity: >97% by HPLC. 








3-[(E)-3-Biphenyl-2-yl-acryloylamino]-4-nitro-benzoic acid 27 (69.0 mg, 0.18 mmol) was 
reduced following the general procedure. The crude reaction mixture was purified by HPLC, 
eluting with acetonitrile (40-95%) in water. The title compound was isolated as a white solid 
(21.2 mg, 0.06 mmol, 33% yield). 
LC-MS: Rt 2.22 mins; m/z (ESI): [M+H]+ 359; [M-H]- 357.  
1H NMR (300 MHz, DMSO-d6): δ = 5.70 (br.s., 2H, NH2), 6.72 (d, J = 8.50 Hz, 1H, Ar-H), 
6.90 (d, J = 15.53 Hz, 1H, CH=CH), 7.30-7.55 (m, 10H, Ar-H & CH=CH), 7.76-7.83 (m, 1H, 
Ar-H), 7.97 (s, 1H, Ar-H), 9.45 (br.s., 1H, NH). 
Purity: >97% by HPLC. 







The Boc-protecting group of 2-{(E)-3-[3'-(tert-Butoxycarbonylamino-methyl)-biphenyl-2-yl]-
acryloylamino}-benzoic acid (39.2 mg, 0.08 mmol) was cleaved according to the general 
 94 
procedure. The title compound was isolated as a white solid (29.5 mg, 0.08 mmol, 96% 
yield). 
LC-MS: Rt 2.22 mins; m/z (ESI): [M-H]- 371.  
1H NMR (300 MHz, DMSO-d6): δ = 2.15 (s, 2H, CH2), 6.45 (d, J = 7.33 Hz, 1H, Ar-H), 6.62 
(s, 1H, Ar-H), 6.82 (d, J = 15.53 Hz, 1H, CH=CH), 7.04 (d, J = 7.62 Hz, 1H, Ar-H), 7.17 
(ddd, J = 8.06, 7.18, 1.17 Hz, 1H, Ar-H), 7.29-7.33 (m, 1H, Ar-H), 7.38-7.50 (m, 2H, Ar-H), 
7.56-7.63 (m, 2H, Ar-H), 7.64 (d, J = 15.53 Hz, 1H, CH=CH), 7.94 (dd, J = 7.47, 1.61 Hz, 
1H, Ar-H), 8.00 (dd, J = 7.91, 1.47 Hz, 1H, Ar-H), 8.55 (dd, J = 8.50, 0.88 Hz, 1H, Ar-H), 
11.28 (br.s., 1H, NH). 
Purity: >98% by HPLC. 









The Boc-protecting group of 4-{2'-[(E)-2-(2-Carboxy-phenylcarbamoyl)-vinyl]-biphenyl-4-
yl}-piperazine-1-carboxylic acid tert-butyl ester (39.2 mg, 0.07 mmol) was cleaved according 
to the general procedure. The title compound was isolated as a pale brown solid (31.8 mg, 
0.07 mmol, 100% yield). 
LC-MS: Rt 1.77 mins; m/z (ESI): [M+H]+ 428; [M-H]- 426.  
1H NMR (300 MHz, DMSO-d6): δ = 3.24-3.30 (m, 4H, (CH2)2), 3.44-3.50 (m, 4H, (CH2)2), 
6.80 (d, J = 15.53 Hz, 1H. CH=CH), 7.08-7.28 (m, 5H, Ar-H), 7.33-7.61 (m, 4H, Ar-H), 7.60 
(d, J = 15.53 Hz, 1H, CH=CH), 7.93 (dd, J = 7.62, 1.47 Hz, 1H, Ar-H), 8.00 (dd, J = 7.91, 
1.47 Hz, 1H, Ar-H), 8.53 (dd, J = 8.50, 0.88 Hz, 1H, Ar-H), 8.83 (br.s., 1H, NH), 11.48 (br.s., 
1H, NH). 
Purity: >96% by HPLC. 










2-[(E)-3-(4’-Piperazin-1-yl-biphenyl-2-yl)-acryloylamino]-benzoic acid 30 (32.0 mg, 0.07 
mmol) was dissolved in dichloromethane (3 mL). Acetic anhydride (17.7 µL, 0.19 mmol) and 
catalytic amounts of triethylamine were added and the resulting solution was stirred at room 
temperature and under argon for 50 minutes. Dichloromethane (2 mL) was added to the 
reaction mixture and the organic layer was washed with 1M hydrochloric acid (5 mL), dried 
over sodium sulfate and concentrated. The crude mixture was purified by HPLC, eluting with 
acetonitrile (50-95%) in water, to give the title compound as a pale yellow solid (17.4 mg, 
0.04 mmol, 49% yield). 
LC-MS: Rt 2.42 mins; m/z (ESI): [M+H]+ 470; [M-H]- 468.  
1H NMR (300 MHz, DMSO-d6): δ = 2.05 (s, 3H, COCH3), 3.16-3.26 (m, 4H, (CH2)2), 3.57-
3.64 (m, 4H, (CH2)2), 6.81 (d, J = 15.53 Hz, 1H, CH=CH), 7.07 (d, J = 8.79 Hz, 2H, Ar-H), 
7.12-7.19 (m, 1H, Ar-H), 7.21 (d, J = 8.50 Hz, 2H, Ar-H), 7.34-7.50 (m, 3H, Ar-H), 7.54-7.58 
(m, 1H, Ar-H), 7.63 (d, J = 15.53 Hz, 1H, CH=CH), 7.92 (dd, J = 7.77, 1.32 Hz, 1H, Ar-H), 
8.00 (dd, J = 7.91, 1.76 Hz, 1H, Ar-H), 8.54 (d, J = 8.21 Hz, 1H, Ar-H), 11.51 (br.s., 1H, 
NH).  
Purity: >99% by HPLC. 








2-[(E)-3-(3’-Aminomethyl-biphenyl-2-yl)-acryloylamino]-benzoic acid 29 (24.9 mg, 0.07 
mmol) was dissolved in dichloromethane (2 mL). Acetic anhydride (15.8 µL, 0.18 mmol) and 
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catalytic amounts of triethylamine were added and the resulting solution was stirred at room 
temperature and under argon for 40 minutes. Dichloromethane (2 mL) was added to the 
completed reaction and the organic layer was washed with 1M hydrochloric acid (4 mL), 
dried over sodium sulfate and concentrated. The crude mixture was purified by HPLC, eluting 
with acetonitrile (40-95%) in water, to give the title compound as a white solid (11.5 mg, 0.03 
mmol, 42% yield). 
LC-MS: Rt 2.33 mins; m/z (ESI): [M+H]+ 415; [M-H]- 413.  
1H NMR (300 MHz, DMSO-d6): δ = 2.06 (s, 2H, CH2), 2.27 (s, 3H, COCH3), 6.81 (d, J = 
15.53 Hz, 1H, CH=CH), 7.00 (dd, J = 7.91, 1.76 Hz, 1H, Ar-H), 7.10-7.17 (m, 1H, Ar-H), 
7.28-7.35 (m, 2H, Ar-H), 7.41-7.49 (m, 3H, Ar-H), 7.50-7.60 (m, 2H, Ar-H), 7.56 (d, J = 
15.82 Hz, 1H, CH=CH), 7.94 (dd, J = 7.62, 1.47 Hz, 1H, Ar-H), 7.98 (dd, J = 8.06, 1.61 Hz, 
1H, Ar-H), 8.51 (dd, J = 8.50, 0.88 Hz, 1H, Ar-H), 9.45 (br.s., 1H, NH), 11.60 (br.s., 1H, 
NH).  









2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (50.0 mg, 0.14 mmol) 
was coupled with the hydrochloric acid salt of 2-methyl-2-(4-bronophenyl) propylamine (31.9 
mg, 0.14 mmol) following the general procedure. The obtained pale yellow solution with 
black precipitate was filtered and purified by HPLC, eluting with acetonitrile (30-95%) in 
water. The title compound was isolated as a white solid (26.0 mg, 0.06 mmol, 45% yield). 
LC-MS: Rt 1.94 mins; m/z (ESI): [M+H]+ 415; [M-H]- 413.  
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1H NMR (300 MHz, DMSO-d6): δ = 1.44 (s, 6H, (CH3)2), 3.14 (s, 2H, CH2), 6.40 (d, J = 
16.70 Hz, 1H, CH=CH), 6.95 (td, J = 7.47, 1.17 Hz, 1H, Ar-H), 7.26-7.49 (m, 7H, Ar-H), 
7.57 (d, J = 8.50 Hz, 2H, Ar-H & CH=CH), 7.84 (dd, J = 7.03, 2.05 Hz, 1H, Ar-H), 7.97 (dd, 
J = 7.91, 1.76 Hz, 1H, Ar-H), 8.58 (dd, J = 8.20, 0.88 Hz, 1H, Ar-H). 
Purity: >99% by HPLC. 







2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (70.0 mg, 0.19 mmol) 
was coupled with 4-(2-nitroethyl)phenylboronic acid (37.8 mg, 0.19 mmol) following the 
general procedure. The obtained solution with black precipitate was filtered and purified by 
HPLC, eluting with acetonitrile (50-95%) in water. The title compound was isolated as a 
white solid (20.2 mg, 0.05 mmol, 25% yield). 
LC-MS: Rt 2.72 mins; m/z (ESI): [M+H]+ 417; [M-H]- 416.  
1H NMR (300 MHz, CDCl3-d): δ = 3.39 (t, J = 7.03 Hz, 2H, CH2), 4.74 (t, J = 7.18 Hz, 2H, 
CH2), 6.55 (d, J = 15.82 Hz, 1H, CH=CH), 7.12 (ddd, J = 8.06, 7.18, 1.17 Hz, 1H, Ar-H), 
7.28-7.46 (m, 7H, Ar-H), 7.60 (ddd, J = 8.64, 7.18, 1.76 Hz, 1H, Ar-H), 7.71 (d, J = 15.82 
Hz, 1H, CH=CH), 7.74-7.78 (m, 1H, Ar-H), 8.12 (dd, J = 7.91, 1.76 Hz, 1H, Ar-H), 8.85 (dd, 
J = 8.50, 0.88 Hz, 1H, Ar-H), 11.32 (br.s., 1H, NH). 











2-{(E)-3-[4’-(2-Amino-1,1-dimethyl-ethyl)-biphenyl-2-yl]-acryloylamino}-benzoic acid 33 
(22.0 mg, 0.05 mmol) was dissolved in dichloromethane (2 mL). Acetic anhydride (12.6 µL, 
0.13 mmol) and catalytic amounts of triethylamine were added and the resulting solution was 
stirred at room temperature and under argon for 50 minutes. Dichloromethane (2 mL) was 
added to the completed reaction and the organic layer was washed with 1M hydrochloric acid 
(3 mL), dried over sodium sulfate and concentrated. The crude mixture was purified by 
HPLC, eluting with acetonitrile (50-95%) in water, to give the title compound as a white solid 
(10.2 mg, 0.02 mmol, 42% yield). 
LC-MS: Rt 2.54 mins; m/z (ESI): [M+H]+ 457; [M-H]- 455.  
1H NMR (300 MHz, MeOD-d4): δ = 1.38 (s, 6H, (CH3)2), 1.93 (s, 3H, COCH3), 3.47 (s, 2H, 
CH2), 6.70 (d, J = 15.53 Hz, 1H, CH=CH), 7.16 (ddd, J = 8.06, 7.18, 1.17 Hz, 1H, Ar-H), 
7.30-7.35 (m, 2H, Ar-H), 7.37-7.48 (m, 3H, Ar-H), 7.51-7.59 (m, 3H, Ar-H), 7.76 (d, J = 
15.53 Hz, 1H, CH=CH), 7.85-7.89 (m, 1H, Ar-H), 8.11 (dd, J = 7.91, 1.76 Hz, 1H, Ar-H), 
8.62 (dd, J = 8.35, 0.73 Hz, 1H, Ar-H). 
Purity: >99% by HPLC. 







2-{(E)-3-[4’-(2-Nitro-ethyl)-biphenyl-2-yl]-acryloylamino}-benzoic acid 34 (18.9 mg, 0.05 
mmol) was reduced following the general procedure. The crude reaction mixture obtained 
was purified by HPLC, eluting with acetonitrile (20-95%) in water. The title compound was 
isolated as a white solid (4.4 mg, 0.01 mmol, 25% yield). 
LC-MS: Rt 1.82 mins; m/z (ESI): [M+H]+ 387; [M-H]- 385.  
1H NMR (300 MHz, DMSO-d6): δ = 2.96 (t, J = 5.42 Hz, 2H, CH2), 3.18-3.25 (m, 2H, CH2), 
6.28 (d, J = 16.41 Hz, 1H, CH=CH), 6.92-6.99 (m, 1H, Ar-H), 7.25-7.35 (m, 5H, Ar-H), 7.39-
 99 
7.48 (m, 4H, Ar-H & CH=CH), 7.77-7.82 (m, 1H, Ar-H), 7.97 (dd, J = 7.77, 1.61 Hz, 1H, Ar-
H), 8.26 (br.s., 2H, NH2), 8.53 (dd, J = 8.21, 0.88 Hz, 1H, Ar-H). 
Purity: >97% by HPLC. 







2-[(E)-3-(2-Bromo-phenyl)-acryloylamino]-benzoic acid methyl ester (60.0 mg, 0.17 mmol) 
was coupled with 4,4,5,5-tetramethyl-2-[(1H)-pyrazol-4-yl]-1,3,2,-dioxaborolane (32.4 mg, 
0.17 mmol) following the general procedure. The obtained solution with black precipitate was 
filtered and purified by HPLC, eluting with acetonitrile (30-95%) in water. The title 
compound was isolated as a white solid (38.4 mg, 0.12 mmol, 69% yield). 
LC-MS: Rt 2.06 mins; m/z (ESI): [M+H]+ 334; [M-H]- 332.  
1H NMR (300 MHz, DMSO-d6): δ = 6.79 (d, J = 15.53 Hz, 1H, CH=CH). 7.13-7.20 (m, 1H, 
Ar-H), 7.33-7.49 (m, 3H, Ar-H), 7.59 (t, J = 7.91 Hz, 1H, Ar-H), 7.75-7.88 (m, 3H, Ar-H), 
7.82 (d, J = 15.24 Hz, 1H, CH=CH), 8.01 (dd, J = 7.91, 1.47 Hz, 1H, Ar-H), 8.59 (dd, J = 
8.50, 0.88 Hz, 1H, Ar-H), 11.58 (br. s., 1H, NH). 
Purity: >96% by HPLC. 
5.4. Conditions of cell-based flavivirus immunodetection (CFI) assay 
A549 or BHK21 cells are trypsinized and diluted to a concentration of 2x105 cells/ml in 
culture media (Hams F-12+2%FBS+1% penicillin/streptomycin). A 100µl of cell suspension 
(2x104cells) is dispensed per well into one 96-well tissue culture plate (Nunc, 96-well clear 
flat bottom, sterile, Nunclone ∆ surface). Cells are grown overnight in culture medium at 
37°C, 5% CO2, and then infected with dengue virus at MOI=0.3 in the presence of different 
concentrations of test compounds for 1hr at 37°C, 5% CO2. The virus inoculum is removed, 
replaced with fresh medium containing test compounds, and incubated at 37°C, 5% CO2 for 
48hrs. The cells are washed once with PBS, and fixed with cold methanol for 10min. After 
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washing twice with PBS, the fixed cells are blocked with PBS containing 1% FBS and 0.05% 
Tween-20 for 1hr at room temperature. Primary antibody (4G2) solution is subsequently 
added and incubated for 3hrs. The cells are washed three times with PBS followed by 1hr 
incubation with horseradish peroxidase (HRP)-conjugated anti-mouse IgG. After washing 
three times with PBS, 3,3',5,5'-tetramethylbenzidine (TMB) substrate solution is added to 
each well, and the reaction is stopped by adding 0.5M sulfuric acid. The plate is read in 
Thermo Labsystems Multiskan Spectrum plate reader at 450 nM for viral load quantification. 
After measurement, the cells are washed three times with PBS, followed by incubation with 
propidium iodide for 5min and the reading of the plate in Tecan Safire plate reader (excitation 
537nM, emission 617nM) for cell number quantification. Dose response curves are plotted 
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